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Abstract
Ovarian cancer is the second most common gynaecological cancer and the eighth-most
common cause of death in Australian women with a five-year relative survival of 46%. Using
a ‘ground-up approach’ and patient involvement, this research project implemented a
sequential mixed methods approach to develop a health-related quality of life outcome
measure across the disease trajectory.

The six key themes identified from initial qualitative data highlighted treatment-related and
psychosocial challenges alongside financial issues, relationships with health professionals,
and patient coping strategies. This informed the generation of items necessary to develop a
draft health-related quality of life tool. A cognitive interviewing technique established the
content validity of the draft items. The final draft scale comprised 38 health-related quality of
life items across three domains: physical health/functioning wellbeing, emotional wellbeing,
and social wellbeing; each rated on a five-point frequency response scale. Field testing and
evaluation of psychometric properties could be the focus of a future study.
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Introduction
The primary objective of this thesis was to define and develop a meaningful healthrelated quality of life (HRQOL) patient-reported outcome measure (PROM) for patients with
ovarian cancer (OC).

This work formed part of a larger research initiative titled ‘The

Continuous Improvement in Care – Cancer (CIC Cancer) Project’. The CIC Cancer project
aims to offer value-based health care (VBHC) in clinical oncology settings in Western
Australia including OC. The main objective of this larger project is to engage and involve
patients, their carers and clinicians to identify and establish an agreed set of outcome
measures pertaining to OC.

This chapter provides a background to OC and clinical care with a focus on the
quality of care and patient involvement. The purpose, scope and relevance of the research are
also discussed in this chapter.

Research Background
Cancer-global and national trends
Cancer, now classified as a chronic illness, is ranked the second leading cause of
death worldwide and causes 1 in every 6 deaths. According to a 2018 report by the
International Agency for Research on Cancer, it was estimated there were 17 million new
cases worldwide and 9.5 million cancer deaths and this is predicted to rise to 27.5 million
new cases and 16.3 million deaths within the next 20 years (American Cancer Society, 2018).

Following a global trend, a recent report by the Australian Institute of Health and
Welfare has found that 1 in 2 Australian men and women will be diagnosed with cancer by
the age of 85 with an estimated 150,000 new cases to be diagnosed by 2020 (Australian
Institute of Health and Welfare, 2019). In addition, the cancer data report by the Australian
Institute of Health and Welfare for the period 1982-2020 shows that the estimated incidence
with all cancers combined has increased from 47,468 to 145,483 whereas actual mortality in
persons increased from 24,915 to 48,099 (Australian Institute of Health and Welfare, 2020).
The growth in the number of cases has impacted hospital expenditure where a recent report
marked that there has been an increase in the hospital-based expenditure for cancer care in
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Australia from approximately $4.5 billion in 2008-09 to around $6.3 billion for patients
diagnosed during 2009–2013 (Goldsbury et al., 2018). Moreover, continued upward pressure
on hospital costs is expected, in part due to improvements in cancer survival rates within
Australia and to early detection and better treatment. The number of people living with a
cancer diagnosis is predicted to double in less than two decades from 350,000 to more than
one million individuals, and double again by 2030 (Fitzmaurice et al., 2019; Wang et al.,
2016).

Cancer care
With more people living longer following a cancer diagnosis, there has been an
international focus in the domain of cancer control and management (Jones et al., 2018) as
cancer survivors often develop a range of post-treatment late-onset side effects (pain, anxiety,
fatigue) and are at an increased risk of disease recurrence (Jones et al., 2018). The quality of
cancer care was first discussed by the Institute of Medicine in 1990 (Lohr et al., 1990). The
study committee of the institute defined quality of care as "the degree to which health
services for individuals and populations increase the likelihood of desired health outcomes
and are consistent with current professional knowledge" (Lohr et al., 1990, pp. 128-129).
However, the increasing need for cancer services, coupled with the complexities of the
disease and its management and rising costs, forms a gap in the delivery of cancer care (Levit
et al., 2013). Reports indicate that lack of patient involvement including patient-clinician
communicational challenges and lack of evidence-based care are barriers in the delivery of
effective cancer care and highlight a need for the development and implementation of new
strategies to improve the quality of cancer care (Miqueu et al., 2019; Walsh et al., 2010).
Patient involvement.
Lack of patient involvement in decision-making and treatment goals with the
clinicians has resulted in fragmented medical care which in turn leads to the current
prioritising of disease-focused treatments (Saini et al., 2017). Patient involvement is vital in
clinical care such as to make informed treatment decisions and participate in healthcare
improvements (McDonald et al., 2013), where a recent study pointed to the significance of
patient-clinician communication as it provides patients the platform to raise and discuss
issues with clinicians thereby forming the shape in subsequent clinical care processes and
outcomes (Greenhalgh et al., 2018). Finally, the lack of a standardised dataset for patient-
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reported outcomes (PROs) that measures changes in patient outcomes over time has made it
difficult to compare and promote treatments in an evidence-based manner. The recognition
for a standardised data set of PROMs that complement the normal clinical measures has been
moved forward under the growing interest in VBHC.

For an effective provision of oncology care, there has been a shift in the healthcare
delivery model from volume to value-based care (Johansen & Saunders, 2017).
Implementation of VBHC into clinical settings uses a patient-centred care approach, whereby
this model promotes better patient health outcomes in an evidence-based manner by reducing
healthcare costs (Porter & Teisberg, 2006). The VBHC design results are reported by both
the care provider through hospitalisation rate and PROs (Porter, 2010). Innately, these
outcomes include tracking patient’s health across the clinical journey and improve HRQOL
in an evidence-based manner (Porter, 2010; Porter & Lee, 2013; Waldrop et al., 2019).

In addition, the involvement of patients with their health care team strengthens and
increases the provision of patient-centred care and thus potentially aid cancer control
(Lavallee et al., 2016). Recent research has noted that this can be achieved by including
PROs in clinical settings that could enhance the delivery of health care (Lavallee et al., 2016;
Tzelepis et al., 2015; Zucca et al., 2014). PROs are patient self-reports that measure health
status and conditions (Basch, 2017) and are about their health and quality of life (QOL),
health care, or treatment related functional status. Patient-reported outcome measures
(PROMs) are the tools used to measure PROs (Kingsley & Patel, 2017). A study at the
Martini Klinik in Hamburg Germany reported that the inclusion of patient-derived
information resulted in significant improvement in patient outcomes for CONDITION (Porter
et al., 2014). The use of PROs is less well incorporated into routine practice in clinical
settings within Australia (Lavallee et al., 2016). As well as needing improved evidence to
support better survival and functional outcomes, clinical care should select validated PROs to
more accurately guide and monitor strategies of clinical care and support.

To help address the need for standardised and meaningful measurement of clinical
and patient-orientated outcomes, the International Consortium for Health Outcome Measures
(ICHOM) has developed numerous standardised datasets for a large number of health
conditions and diseases, including various cancers (Ong et al., 2017; Zerillo et al., 2017).
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Implementation of a standardised dataset can provide a platform for comparison of outcomes
across health care providers and patients for effectiveness and cost-benefit (Ohno-Machado,
2014). ICHOM datasets have already been developed for several cancer types that consist of
colorectal, lung, breast and prostate (Mak et al., 2016; Morgans et al., 2015; Ong et al., 2017;
Zerillo et al., 2017). Unfortunately, there are currently no internationally agreed datasets for
OC.

Purpose of the Study
The primary aim of this study is to address this current lack of a PROM tool designed
for OC. While a number of survey instruments have been previously developed to measure
signs and symptoms and overall HRQOL in women with OC, most were not developed in
consultation with cancer patients and their carers and/or were designed for monitoring
patients just through their chemotherapy phase of treatment rather than the whole patient
journey and are as follows:
• European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire- Ovarian Cancer Module 28 (EORTC QLQ-OV28) (European
Organisation for Research and Treatment of Cancer Quality of Life, 2019)
• Functional Assessment of Cancer Therapy Ovarian Cancer (FACT-O)
(FACIT.org, 2019)
• FACT ovarian cancer symptom index (FOSI) (FACIT.org, 2020b)
• Measure of Ovarian Symptoms and Treatment concerns (MOST) (King et al.,
2018)

Thus, this study utilised patients with OC to identify an agreed specific set of PROM
using a sequential mixed methods approach through a holistic research process via semistructured telephone interviews and focus groups and cognitive interviewing (CI) using the
‘think aloud’ technique to reach consensus on the initial development of HRQOL PROM
using both consumer and clinician input. Findings from interviews and focus groups formed
the basis of the CI phase. The CI process outcomes informed a drafted outcome measure. In
the future, identification and content prioritisation of the developed PROM will then be
piloted to measure its psychometric properties and later on will then be piloted anonymously
in patients for validation. Together with other newly developed outcomes, this will help
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determine what is important to patients in order to directly improve the lives of those
diagnosed with OC.

Overarching aim
This study aimed to develop a meaningful OC-specific HRQOL PROM through
patient involvement.

Research Questions
The overarching question for this study was “What are the key outcomes associated
with the disease and treatment for patients with OC that can be self-reported and utilised in
both clinical trials and clinical practices?” with the following specific research questions
being:
1.

What are the key outcome priorities identified and described by women with OC?

2.

From the comprehensive consumer-driven and identified list of outcomes, what specific
outcomes contribute to accurately measuring the HRQOL of women diagnosed with
OC?

3.

Are the key outcomes identified through these processes different from existing tools

and if so, how are they different?

Significance
Western Australia Cancer Plan 2020-2025 is a five-year plan that lays out a strategy
for providing the best possible cancer care to the people of Western Australia. According to
the report, Western Australia outperformed the rest of Australia, having the highest five-year
survival rates for several cancers, including ovarian cancer (Government of Western
Australia Department of Health, 2020).
It is anticipated that this study will contribute to improvements in the treatment and
management of patients with OC and help develop better information about the types and
impact of PROs with this disease. This study involved patients throughout all phases of the
development of the HRQOL PROM tool. It will enable patients to provide detailed
information

regarding

aspects

of

OC-related

diagnosis/treatments/disease

progression/recurrence that are important to them and to their health care providers in a
timely and effective manner. Through further validation, it is envisaged that the standard set
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of PROMs developed from this study will enable comparisons of OC treatments and facilitate
long-term improvement in OC care both within and outside individual clinics.

Thesis structure
The structure of the thesis is as follows:
•

Chapter One provides an overview of cancer and the quality of care provided to the
patients. This chapter also summarises the challenges in improving the standard of
treatment by transitioning to value-based care and engaging patients with their health
team.

•

Chapter Two presents a comprehensive literature review of OC and four existing
OC-specific PROM tools. This chapter also discusses the limitations of each tool and
argues that patient involvement is essential in the development of a PROM tool
because patient experiences and perspectives are needed to incorporate outcomes that
matter most to patients.

•

Chapter Three details the study methodologies utilised in this thesis.

•

Chapter Four reports on a qualitative study on patient and career perspectives on
their clinical journey as published in Patient Related Outcome Measures (2020).

•

Chapter Five reports the initial development of an OC-specific HRQOL PROM
through the utilisation of cognitive interviewing as a manuscript submitted to Patient
Related Outcome Measures which is under peer review.

•

Chapter Six the final chapter, comprises a discussion that addresses the research
questions, conclusions and recommendations for future research, from the qualitative
work conducted in this thesis.

The reference list of chapters four and five are listed in compliance with each chapter as they
are presented in a manuscript format. However, a compiled full reference list is provided at
the end of this thesis for the remaining chapters.
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Chapter Two: Review of literature
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Introduction
This chapter provides a comprehensive literature review regarding OC, the use of
existing OC specific PROM tools and their limitations are discussed in this chapter. The
chapter commences with an overview of OC and how factors like symptomatology and
treatment influence the survival course of patients diagnosed with OC. HRQOL is then
discussed, accompanied by a brief definition of QOL. The chapter explains the four tools
developed specifically for OC-diagnosed patients. Finally, the chapter discusses the
limitations and gaps of these four tools, showing that the development of an OC specific tool
is necessary which is discussed in chapters three and four.

Ovarian cancer
Although the incidence of OC is low compared to other female cancers, the morbidity
and mortality rates are relatively high (Chase & Wenzel, 2011). In Australia, OC is the eighth
most commonly diagnosed cancer among women with 1532 new cases diagnosed in 2020
and the second most common cause of death due to gynaecological cancers with an
estimation of 1068 deaths from OC in 2020 (Cancer Australia, 2021). In Western Australia,
115 cases are being diagnosed every year, with an average five-year survival rate of less than
50% (Department of Health Western Australia, 2017). Prognosis depends on factors such as
age, genetic factors, general health, tumour stage, response to treatments and macroscopic
residual disease at the completion of surgery (Burges & Schmalfeldt, 2011).

Factors Impacting Clinical Diagnosis and Survival
Symptomatology
Ovarian cancer affects women of all ages but is most commonly diagnosed after
menopause with major risk factors including advancing age and a family history of ovarian
and breast cancer (Doubeni et al., 2016). Women with early-stage disease are often
asymptomatic. Around 75% of women are diagnosed with an advanced tumour where
symptoms may be nonspecific (Doubeni et al., 2016). The United Kingdom Collaborative
Trial of Ovarian Cancer Screening did not demonstrate a significant decrease in OC mortality
with screening and there is currently no effective population-level screening test for OC
(Henderson et al., 2018; Jacobs et al., 2016; Natarajan et al., 2018).
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The four groups of symptoms that have been found in retrospective studies to be more
commonly associated with OC are abdominal/pelvic pain, bloating/abdominal distension,
bladder irritability (frequency, urgency and nocturia) and early satiety (early fullness when
eating) (Ebell et al., 2016; Goff et al., 2007; Goff et al., 2004). As many of these symptoms
are indicators of other diseases, such as gastrointestinal disease (Bankhead et al., 2008), the
presence of OC is often resulting in misdiagnosis or delayed diagnosis (Robinson et al.,
2012).

Diagnosis
In the absence of screening tools and specific symptoms, diagnosis of OC relies on
pelvic examination, various imaging investigations and measurement of the tumour specific
blood marker, CA125 (Badgwell & Bast, 2007). Unfortunately, circulating levels of CA125
vary by disease stage (Badgwell & Bast, 2007) and associations with other health conditions
like pregnancy, menstruation, pelvic inflammation make it inefficient as a screening strategy
(Fritsche & Bast, 1998; Gupta & Lis, 2009). Recent outcomes from the largest OC screening
trial to date, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), reported
annual multimodal screening using the longitudinal CA125 Risk of Ovarian Cancer
Algorithm and pelvic ultrasound failed to reduce mortality rates in the screened population
compared with no screening, suggesting more productive outcomes may come from
screening high-risk women (family history or with BRAC1/2 mutations) or further
exploration of OC tumour DNA biomarkers (Jacobs et al., 2016; Menon et al., 2018).

In the absence of an effective screening tool or specific symptoms, the majority of
cases of OC are diagnosed at advanced stages (III & IV) (Miranda & Ahmed, 2016) often
resulting in adverse disease outcomes (Buys et al., 2011). While there is an urgent need to
develop new strategies for screening and early detection, other studies have demonstrated that
routine review following treatment is not effective in improving survival, quality of care and
relieving anxiety due to lack of high-quality evidence for follow-up care (Cancer Australia,
2012; Le et al., 2016).
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Clinical management
Whilst OC has multiple cellular origins (Cardenas et al., 2016), 80% are epithelial
(Natarajan et al., 2018). Treatment of epithelial ovarian cancer is a combination of both
surgery and chemotherapy. While fertility-preserving surgery with unilateral salpingooophorectomy may be offered to younger women with unilateral non-metastatic cancer
(Stage 1A), those with more advanced cancer undergo radical surgery that may include total
hysterectomy, bilateral salpingo-oophorectomy, omentectomy, splenectomy, diaphragmatic
resection, pelvic peritonectomy, bowel resection and colostomy. Disease deemed nonresectable, or patients did not fit for surgery due to poor performance status, comorbidities
and/or malnutrition, are treated by neoadjuvant chemotherapy followed by an interval
cytoreductive surgery after 3-4 chemotherapy cycles (Natarajan et al., 2018).

Standard first-line chemotherapy for epithelial ovarian cancer involves six, threeweekly cycles of intravenous or intraperitoneal administration of a platinum-based drug such
as carboplatin, with a taxane, usually paclitaxel (Cristea et al., 2010; Schwab et al., 2014).
Patients undergoing chemotherapy often experience nausea, vomiting, hair loss, cognitive
dysfunction, fatigue, changes in sexual functioning, peripheral neuropathy and reduced QOL
(Kayl & Meyers, 2006).

Although there has been some improvement in OC control in the last two decades that
has resulted in increased survival (Arnold et al., 2019). Approximately 80% of women with
advanced OC relapse (median time to first recurrence 18 months) which is usually eventually
fatal due to the emergence of drug resistance (Liu et al., 2018; Lloyd et al., 2015).

While platinum-based therapy continues to be the principal regimen used to treat
tumours that recur at least 6 months after prior therapy, the response typically persists for just
a few months and with each additional course of therapy, the treatment-free period usually
grows shorter before the tumour is considered ‘platinum resistant' (Luvero et al., 2014). The
sequential use of chemotherapy regimens and the incorporation of molecularly targeted
treatments have been shown to extend the median survival time of patients with OC and
palliate symptoms to several months, but it is rarely curative (Luvero et al., 2014).
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Clinical trajectory: patient concerns
While clinical management of cancer patients routinely addresses pain (Jacox et al.,
1994) and the side-effects associated with chemotherapy (Cassidy & Misset, 2002), cancer
patients have also been shown to have nearly twice the level of psychological distress of the
general population (Hinz et al., 2010) exhibiting severe emotional distress particularly during
diagnosis and the initial treatment period (Andersen et al., 1989; Zenger et al., 2010). Similar
observations have been made in women with OC (Bodurka-Bevers et al., 2000) with another
study reporting greater levels of psychological distress occurred in younger patients, patients
who had more recently been diagnosed with ovarian cancer and those with more advanced or
recurrent disease (Norton et al., 2004). OC patients are faced with additional difficulties with
their physical and social wellbeing, fatigue and pain (Osoba et al., 1994). Similarly, in
patients with advanced cancer, distress levels are often exacerbated by feelings of being a
burden to others (Engelmann et al., 2016), fear of recurrence (Crist & Grunfeld, 2013) and/or
death (Bachner et al., 2011).

Many new cancer treatments are being evaluated solely based on increased survival
and without evaluating details on other benefits and shortcomings of these treatments. As
such, there has been a call for clinical trials to measure QOL and other PROs to create a more
comprehensive assessment of the treatment protocol and provide patients with greater
knowledge of potential impacts (Thomas, 2016; Wilson et al., 2018). Similarly, the
importance of monitoring QOL symptoms in patients with advanced cancer as part of clinical
management has been shown to result in fewer emergency department visits and hospital
admissions, longer duration of palliative chemotherapy and superior quality-adjusted survival
than patients receiving usual care (Basch et al., 2016).

Quality of Life Measures
Whilst functional status had been used in the social sciences literature since the early
1900s, new measures that provided a level of objective scoring for use in health disciplines
did not appear until around the middle of the century (Prutkin, 2002). These measures
became more popular from the 1970s and became known as QOL (Pennacchini et al., 2011).
Within the health domain, QOL often reflects a multidimensional aspect of physical,
psychological, functional and social wellbeing amongst patients (Gotay, 1996) while other
dimensions such as spirituality, sexuality, treatment satisfaction can also be important (Cella
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& Tulsky, 1990). These dimensions are interrelated as a recent study finding suggests that
alterations in one QOL dimension can impact expectations in other dimensions too (Jitender
et al., 2018).

QOL measures are used in multiple ways in health care. These include (Fitzpatrick et
al., 1992):
•

Screening and monitoring for psychological problems in individual patient care;

•

Measuring outcomes in health services and/or research;

•

Clinical trials;

•

Assessment of cost-utility;

•

Medical audits;

•

Population surveys of perceived health problems.

The COVID-19 coronavirus pandemic remains our largest public health threat in
decades, influencing all dimensions of everyday life (Liang et al., 2020). Although we are
seeking to defeat coronavirus with collaborative management procedures, minority
communities such as those afflicted with cancer should have special focus and importance as
they are faced with bigger challenges such as disease progression and lack of treatment
choice due to self-isolation protocols (The Lancet, 2020). Thus, it is important to evaluate
their QOL. In fact, a recent study found that due to COVID-19, financial challenges, altered
family and social life impacted the QOL of cancer patients. In addition, these challenges were
associated with a considerable decline in the welfare and functioning ability of the patients
(Ciążyńska et al., 2020).

Health-related quality of life (HRQOL)
While the term, QOL, is still used within the social sciences literature based on
constructs such as economic performance and social progress, new measures that pertain to
general health well-being or outcomes surrounding a specific disease, often called HRQOL,
are today common within the health sciences literature (Post, 2014). Multiple definitions
exist. In essence, HRQOL primarily focuses on the impact that a disease and its treatment
have on various aspects of patients’ lives including physical, functional, psychological and
social (Šumskienė et al., 2015).
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One essential purpose for measuring HRQOL is to improve and broaden knowledge
on the spectrum of patient issues. HRQOL instruments are designed as general PROMs such
as the Short Form Survey (SF-36) (Ware & Gandek, 1998) which can be used within broad
disease groups (Bousquet et al., 1994; Kemmler et al., 1999), or PROMs that are limited to
those with specific diseases such as breast cancer and gynaecological cancers (Diaz-Buxo et
al., 2000) and/or symptoms (Zigmond & Snaith, 1983). Research shows that the joint
administration of standardised and disease-specific tools will lead to better evaluation of both
global and specific HRQOL attributes (Loria et al., 2012; Šumskienė et al., 2015).

With a plethora of HRQOL instruments now available, concerns have been raised
about the reliability, validity, reproducibility, cross-cultural applicability, sensitivity to
change, and interpretability of these tools (Naughton & Wiklund, 1993; Okamoto et al., 2003;
Soni et al., 2002). At present, most HRQOL measures are limited to use within clinical trials
and formal evaluation studies where they are used alongside other demographic and clinical
information, but there is increasing interest to incorporate these tools into routine clinical
management (Basch et al., 2016; Testa & Simonson, 1996).

In addition to aiding the decisions around treatment options, HRQOL and symptom
measures can be useful in assisting with end-of-life decisions being made by clinicians in
consultation with their patients. Price et al showed that HRQOL declined sharply in women
with OC from six months prior to death with anorexia, nausea and pain increasing towards
the end of life (Price et al., 2013). This provides a valuable example of how HRQOL PROs
could shift treatment goals towards symptom palliation. In addition, studies also highlight
that it is also important to carefully monitor the HRQOL of advanced cancer patients in
clinical settings due to the potential problem of fearing death. (Detmar et al., 2000; Edwards
et al., 2010; Saeteren et al., 2011; van Roij et al., 2018). Moreover, measuring HRQOL when
treating advanced cancer is vital, as it increases health professionals’ understanding of
patients' changing priorities and would enhance treatment outcomes such as fewer
emergency/hospital visits and improved survivorship (Basch et al., 2016; Etkind et al., 2015).
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Patient-Reported Measures and Outcomes (PROMs)
The role of the patient in providing information and participating in clinical decisions
has become increasingly clear in the last decade or two. Information provided by the patient
without clinician modification and/or interpretation is termed a patient-reported outcome
measure (PROM) (Meadows, 2011). These measures can be general or disease specific and
are defined as information that is directly reported by the patient without interpretation of the
patient’s response (Meadows, 2011) and pertains to the patient’s health, QOL, or functional
status associated with health care or treatment (Moss & Havrilesky, 2018; Weldring & Smith,
2013). All PROM instruments need a number of attributes that include validity, reliability,
minimal administrative and respondent burden, and appropriate language and cultural
adaptations (Lipscomb et al., 2007). They should be short enough for patients to complete
within 15 minutes and be easily comprehended (Basch et al., 2012).

It has been noted that many researchers use the term HRQOL to describe any
phenomenon or latent trait that has been developed directly from patients (U.S. Department
of Health and Human Services FDA Center for Drug Evaluation and Research, 2006), and
others see this as “patient reported” but question whether this is of direct concern to the
patient (Doward & McKenna, 2004). And herein, lies an important distinction – does the
collected information actually have importance or concern to the patient? While this
distinction is acknowledged in a paper by Friedlander and King (Friedlander & King, 2013),
they also argue for the importance of consistency in using HRQOL/PRO measurements, their
analysis and reporting in OC trials through the establishment of guidelines such as
CONSORT-PRO & SPIRIT-PRO (Calvert et al., 2018; Joly et al., 2017). These guidelines
recommend six checklist items be considered for randomised, clinical trials where PROs are
the primary or secondary endpoints. These include: that the PRO be identified as a primary or
secondary outcome(s) in the abstract; a description of the hypothesis of the pros and relevant
domains is provided; evidence for the quality and efficacy of the instrument(s) must be
provided; a methodological method for working with incomplete data must be specifically
stated; and generalizability of findings to other communities and clinical experience must be
addressed. In further, the 16-items recommended by the SPIRIT-PRO guidelines need to be
addressed and included in clinical trial protocols (Calvert et al., 2013; Calvert et al., 2018).
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Importance of patient involvement in PROM development.
Patient involvement has a profound impact on the development of PROM tools as it is
only the patients who can determine outcome relevance and comprehensibility of the tool
(Staniszewska et al., 2011; Trujols et al., 2013). In addition, research shows lack of patient
involvement affects the sensitivity, validity and response of the tool (Fossey & Harvey, 2001;
Meadows, 2011). Thus, patient involvement is a key factor when developing a new tool to
measure PROs. As PROMs are developed to reflect upon patient perspective, it is essential to
involve patients throughout the development processes (Kirwan et al., 2011; Wiering et al.,
2017). As reported in a recent review of 189 studies that described the development of 193
PROMS, over a quarter had no patient involvement at all, while some patient involvement
took place in the development of most PROMs, but only 6.7% of patients were involved in
all aspects of the development. In addition, patient involvement did not increase in PROM
development studies over time (Wiering et al., 2017). Even though certain limitations exist
such as the availability of resources including time and money, PROMs developers agree that
it is a necessity to involve patients during PROM development (Wiering et al., 2017).

Cancer Specific PROMs
Although clinical trials involving cancer patients utilise a number of general PRO
tools, (such as the hospital anxiety and depression scale (HADS), NCI PRO-Common
Terminology Criteria for Adverse Events (CTCAE), Rotterdam symptom checklist,
Depression, anxiety and stress scale 21 (DASS-21), Patient-reported outcomes measurement
information system (PROMIS) and Medical outcomes study (MOS) short form survey 36
(SF-36)), several validated tools exist for cancer-patients (Moss & Havrilesky, 2018). Within
these, some are designed for patients with specific cancer types, including gynaecologic
cancers (Moss & Havrilesky, 2018).

Ovarian Cancer specific PROMs for HRQOL
European Organization for Research and Treatment of Cancer (EORTC).
An international non-profit organisation for cancer research was established in 1962
under Belgian legislation as the Groupe Européen de Chimiothérapie Anticancéreuse
(European Organisation for Research and Treatment of Cancer, 2020). The foundation seeks
to enhance the survival and quality of life of patients diagnosed with cancer. Over five
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decades, substantial progress has been made in clinical science from the treatment and
control of cancer to the evaluation of patient QOL. The EORTC developed a tool called the
EORTC Quality of Life Questionnaire for Cancer Patients (EORTC QLQ-C30), one of the
widely used cancer-specific QOL questionnaires (Moss & Havrilesky, 2018). The
questionnaire comprises 30 items describing five functional scales: physical, role, emotional,
social and cognitive; overall assessment of general health and QOL; and nine cancer
symptom subscales (pain, fatigue, nausea, vomiting, constipation, diarrhoea, dyspnoea,
problems with sleep, appetite) (Aaronson et al., 1993). The EORTC further developed a
specific ovarian cancer module, QLQ-OV28, which is supplemented with QLQ-C30. QLQOV28 contains 28 items that assess body image, sexuality and attitude to disease/treatment,
abdominal/gastrointestinal

symptoms,

peripheral

neuropathy,

hormonal/menopausal

symptoms and other chemotherapy side-effects (European Organisation for Research and
Treatment of Cancer Quality of Life, 2019).

Functional Assessment of Chronic Illness Therapy.
Functional Assessment of Chronic Illness Therapy (FACIT), formerly known as
Functional Assessment of Cancer Therapy (FACT), was introduced in the 1980s. The FACTG (Functional Assessment of Cancer Therapy – General) was the original questionnaire
leading to the creation of the broader quality of life instruments, FACIT (FACIT.org, 2020a).
The FACT-G is another commonly used HRQOL tool among cancer patients that can be
augmented by site- and/or treatment-specific modules (Moss & Havrilesky, 2018). This
survey evaluates the effects of cancer treatment in four domains: physical social/family,
emotional and functional. Likewise, EORTC, FACIT have developed ovarian cancer-specific
modules (FACT-O and FACT-Ovarian Symptom Index (FOSI)), whereby these modules are
offered with FACT-G items measuring QOL factors (Friedlander & King, 2013). The FACTO questionnaire utilises the 27 items of FACT-G that measure four core domains, additional
12 items (body image, sexuality, abdominal/bowel symptoms) specific to ovarian cancer
(FACIT.org, 2019). Derived from the FACT-O, FOSI is a brief index, containing eight items
that measure the symptom response to OC care (FACIT.org, 2020b).

Measure of Ovarian Symptoms and Treatment concerns.
A new tool that assesses patient-reported advantages and disadvantages has recently
been introduced to assess the effectiveness of chemotherapy as a palliative treatment in
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women with symptomatic ovarian cancer (Friedlander et al., 2014; King et al., 2014). In their
study, 126 patients receiving palliative chemotherapy completed 5 validated health-related
quality-of-life questionnaires (EORTC QLQ-C30, QLQ-OV28, FACT-O, FOSI and
gynaecologic cancer-specific Symptom Representation Questionnaire) before starting
treatment and before each treatment cycle. Through a mix of study participant interviews and
statistical analysis, they identified a new tool known as the Measure of Ovarian Symptoms
and Treatment (MOST), which has three versions. MOST-T35(v1) consisted of 35 items of
which 15 assess disease symptoms, 17 assess adverse effects of treatment, and 3 assess wellbeing (physical, emotional and overall). This tool underwent further development which
reduced it to 24 items, MOST-T24(v2), comprising five subscales describing abdominal
symptoms

(MOST-Abdo),

disease

or

treatment-related

symptoms

(MOST-DorT),

chemotherapy-related symptoms (MOST-Chemo), psychological symptoms (MOST-Psych),
and MOST-Well-being (King et al., 2018). The third version, MOST-S27, advised to be used
to monitor patients undergoing therapy with the first-line treatment contains 27 items in
which 17 items assess disease symptoms, 3 items assess well-being, 5 items assess treatment
difficulties, and two items aimed to identify and assess additional symptoms (Gynecologic
Cancer Intergroup, 2020).

Limitations of ovarian cancer specific PROMs for HRQOL
The two core instruments and their OC modules pose several limitations with all four
tools methodologically distinct. EORTC and FACT are generic tools used in cancer patients.
A study that compared EORTC QLQ-C30 and FACT-G found that the scales overlapped
considerably (Kemmler et al., 1999). Despite the major overlap, previous studies have
however shown that social dimensions of HRQOL are distinct from both instruments
(Blazeby et al., 2005; Holzner et al., 2006; Luckett et al., 2011)A recent study indicated that
the EORTC QLQ-C30 assesses the relationship of physical disabilities with family and social
life, while the social domain of FACT-G measures family and friends' social support and
found

that

the overall quality of life measurement varied

between the two instruments

(Darling et al., 2020). Since EORTC QLQ C-30 and FACIT-G are administered in patients
with various types and stages of cancer, these measures are not considered applicable to
patients receiving palliative care. Because the spiritual domain is particularly relevant at the
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terminal phase, this domain is not included in these current measuring instruments,
challenging its measurement properties (Albers et al., 2009).

Recent research investigated the incorporation of EORTC measures into clinical
practice and found that the EORTC QLQ-C30 has its own challenges such as duration,
frequency and the evaluation of scores by health professionals (Wintner et al., 2016).
Moreover, a recent study evaluated the psychometric properties of 39 self-administered
HRQOL tools with advanced cancer patients. The study results revealed that EORTC QLQC30 had good content and construct validity. However, psychometric properties of the
EORTC

QLQ-C30

such

as

reliability,

internal

consistency,

responsiveness

and

interpretability were unclear and the psychometric properties of FACIT-G were incomplete
as they were inadequately evaluated on the study participants (van Roij et al., 2018).

The accuracy of measuring patient HRQOL using current validated instruments is
potentially challenged if OC patients are to be administered with these instruments, as this
may not truly represent the challenges and complexities experienced by women with OC
during the clinical trajectory. A 2005 study indicated that although these instruments have
similarities, they cover various aspects of the QOL of a cancer patient. The study emphasised
that the choice of instrument, therefore, depends on the nature of the individual study
(Blazeby et al., 2005).

Moreover, there was only minimal or no patient participation during the development
(Aaronson et al., 1993). For example, during the development of QOL domains of FACT-O,
patient involvement only occurred during the initial stages of development by conducting
open-ended interviews and later in the first validation process. It is to be noted that
participated patients had mixed cancer diagnoses (Cella et al., 1993) wherein it could be a
problem of not being designed for a specific cancer type.

The identified limitations of the existing tools relating to the questionnaire content
and its psychometric properties denote that the development of this OC-specific tool is
necessary as it will be unique in its methodology.
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Conclusion
The potential of HRQOL PROMs to improve the care of cancer survivors is
increasingly recognised because they allow accurate measurement of a range of outcomes
throughout a patient’s clinical trajectory. Research has demonstrated that involving patients
during each stage of PROM development can yield a PROM instrument that is valid and
comprehensible to patients. Further, the implementation of these measurement tools into both
clinical care and research serves as a key component in delivering value-based patientcentred care (Johansen & Saunders, 2017). While validated ovarian cancer PROM
instruments do exist, they are few and may not adequately cover associated symptoms during
the whole disease trajectory (European Organisation for Research and Treatment of Cancer
Quality of Life, 2019; FACIT.org, 2019, 2020b; King et al., 2018). These tools have only
incorporated minimal patient involvement during their developmental stages which are vital
for a PROM development (Wiering et al., 2017). Measuring patient experiences such as
disease and treatment related symptoms (frequency, severity and duration) and HRQOL, can
aid in assessing individual treatment progress and disease recurrence.

This thesis sought to address these gaps by undertaking a “ground-up” approach to
PROM development by engaging with ovarian cancer patients, and their carers and
clinicians, to identify a set of relevant and meaningful measures that have both personal and
clinical significance. The aim of this research was to enhance our understanding of the
outcomes that matter most to women with ovarian cancer and to ultimately develop a PROM
tool that will enable better identification and earlier treatment of symptoms during the entire
course of the disease.

Chapter summary
This chapter provided a comprehensive literature review of existing OC-specific
PROM tools. Limitations in methodological approaches, including lack of validation of
psychometric properties and patient involvement in their development, were discussed. These
identified gaps underlined the need to establish an OC-specific HRQOL PROM tool through
patient involvement which is addressed in the primary (chapter four) and secondary (chapter
five) research of this thesis.
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Chapter Three: Methodology
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Introduction
This chapter describes the three qualitative approaches used in the two studies
conducted. As this thesis employed a sequential mixed methods approach, the findings of the
primary piece of research paved the way to the development of the construction of the
secondary piece of research. The two studies have been submitted for publication, details
about how each study was undertaken are primarily described in Chapters 4 and 5 so this
Chapter provides an overview.

Design and Methodology
The overarching methodology for this study is sequential mixed methods. A
sequential mixed methods approach involves conducting a sequence of phases of either
quantitative or qualitative data collection or analysis, followed by the analysis of the second
and subsequent phase (Berman & Tufts, 2017). The findings of the preceding phase inform
the development and conduct of the second and subsequent phases of the study. The
triangulation of data in each phase ensures that the study findings are validated through the
convergence of information from the qualitative data. Triangulation in qualitative research
enables the development of a comprehensive and broader understanding of phenomena
(Patton, 1999). This approach can be used as data source triangulation when applied to
qualitative analysis. Data source triangulation requires data collection from people,
organisations, or families to obtain different viewpoints and data validation (Carter et al.,
2014).

The process followed by the candidate is best practice in scale development (Boateng
et al., 2018) whereby item generation as the first step includes both deductive and inductive
methods. Deductive includes a scoping exercise of existing scales as well as an extensive
literature review. Inductive include qualitative data collection, which when combined with
the literature review, provides a comprehensive list of items for inclusion n in the pilot scale.
Best practice in scale development will include both inductive and deductive methods.
Researchers developing PROMS have employed similar qualitative approaches such as
community conversation as part of field notes, qualitative interviews, focus groups, cognitive
interviewing for their scale development (Chhina et al., 2021; Fenwick et al., 2013; Lessard
et al., 2019; Wright et al., 2021).
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Thus, an integration of various qualitative approaches into this research was
beneficial as it can provide great depth of knowledge and enable to investigate identified
issues as a whole (Almalki, 2016). As this study utilised a sequential approach, it was
conducted in two distinctive phases. Collection and analysis of data were conducted at
several stages. As noted earlier, each phase was dependent on the previous phase to inform
the choice of how to proceed to the next subsequent phases, data collection at various stages
was essential. The study design is visually represented in Figure 1.

Figure 1
Developmental stages of HRQOL PROM tool for patients diagnosed with OC

Phase One:
[Preliminary work]
Community conversation
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Comprehensive Literature
review

(15 women with OC, two
consumer advocates and a
clinician)

Articles with PROMS to be
identified through PubMed

Phase One:
Semi-structured interviews

Phase One:
Focus groups

13 women with OC

13 women with OC
and two consumer advocates

Qualitative analysis
Item generation for PROM tool

Phase Two:
Cognitive interview [Concurrent
Think-aloud procedure]
14 women diagnosed with OC

Qualitative analysis
Item refinement & validity
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Phase One- Qualitative Interviews and Focus Groups
Drawing on the findings from the literature review, Phase One directly engaged with
patients with OC, their carers and a clinician through a community conversation event, semistructured telephone interviews and focus group discussions. These processes sought to hear
the “patient’s voice” and identify their view of the health symptoms and outcomes that matter
most to them as they traverse their disease pathway. Combined with an extensive literature
review and existing cancer specific tools, this phase aimed to generate and compile items
necessary for the PROM tool development using three qualitative approaches. Ethics
approval for this study was granted by the Human Research Ethics Committee at UNDA
(Appendix 1).

Community Conversation
Phase One commenced by performing ‘grass-roots’ work within the community of
OC patients through community conversation to promote community mobilisation. The key
purpose of this initial step was to listen to the community’s needs attentively and most
importantly, encourage members to think, discuss and explore the main causes and
underlying issues behind their health problems.
While not a formalised research methodology, community conversation is used as a
qualitative research tool for communicating and engaging key stakeholders in identifying
various dynamics of the type that is fundamental to the qualitative study (Trainor,
2018)(McKenzie & Hanley, 2014). It also allows the researcher to investigate and highlight
viewpoints and perceptions of a given population (Patton, 2015). To provide an insight into
the range of issues expected to be divulged through the interview and focus group sessions,
and to help ensure these events are developed and conducted in a manner that is both
welcoming, safe and supportive for these patients, an initial “community conversation” was
held with a small number of 15 women with ovarian cancer, two consumer advocates and a
clinician. The event was facilitated by an independent consumer representative group and a
gynaecologist with experience in this area of gynaecological cancers to explore some of the
key issues of personal importance to these key stakeholder groups that were used to inform
the subsequent steps in this phase of the work.
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Semi-structured Interviews
Phase One then comprised engaging with women who have been diagnosed with OC
using a semi-structured interview approach, with the purpose of gaining a comprehensive
understanding of their health concerns at a personal level as the first step in identifying the
specific items the developed PROM will utilise. Upon recruitment, participants were
provided with a participant information sheet (Appendix 2) and consent form (Appendix 4)
that required to be signed and returned prior to the scheduled interview.
Semi-structured interviews are one of the most widely used qualitative data collection
approaches that aim to obtain rich information and explore the "insider perspective" of a
participant (Brinkmann, 2013). One characteristic advantage of this method is that it allows
participants to speak freely and provides the opportunity to obtain new and novel
information. Another advantage is that interviewer has the flexibility to focus the
conversation on issues relating to the study raised by the interviewees (Brinkmann, 2013).
Thirdly, questions can be prepared in advance so that the interviewer demonstrates
competence and knowledge about the subject matter during the interview, thereby allowing
two-way communication between interviewer and interviewee. Moreover, information-rich
data can be collected in a time- and resource-efficient manner thereby producing analogous
and reliable qualitative data (Barrett & Twycross, 2018).

Focus groups
Following the individual interviews, women with OC and their carers were invited to
participate in two focus groups to further discuss and validate the findings from the interview
process and to explore a broader understanding of health-related outcomes in this context. A
secondary approach is especially vital for this qualitative research as it provides data
triangulation and a balance across the disease spectrum that may not be fully explored in a
one-on-one, face-to-face interview. Recruited participants were provided with a participant
information sheet (Appendix 3) and ensured that the signed consent form (Appendix 5) was
returned prior to the task commencement.
Focus groups are a useful data collection tool in qualitative research as they enable indepth discussions of sensitive issues and provide a platform for sensitive topics to be raised
(Jordan et al., 2007). Focus groups will allow those affected by OC to share their experiences
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or views similar to others (Liamputtong, 2013). Interaction amongst participants is a
significant feature of focus groups and is useful in providing a platform for an open
conversation, where discussions and topics are free-flowing and the comments among
participants stimulate recall in others. Another advantage of focus groups is that they
eliminate the chance of misunderstanding the research questions asked, as participants have
the opportunity to raise any query during the meeting (Liamputtong, 2013). Having no prior
knowledge about the participants, this research tool is particularly useful for this study to
explore and examine their knowledge and experience.
By using these qualitative approaches, the identified outcomes were then analysed
and categorised in accordance with the major themes which contributed to the construction of
an initial draft set of items to be administered with women diagnosed with OC using CI in
Phase Two.

Phase Two - Cognitive Interviewing
To be used routinely in a clinical setting, any PROM information needs to be
standardised and validated. Using a cognitive interviewing (CI) approach, the purpose of this
phase of the study was to refine and validate the wording of the items developed from the
information collected during Phase One. Common themes identified from all consumer
consultation procedures (including the initial pilot project patient interviews) and the
literature relating to coping with cancer were collated. Also, more domains and items were
generated during CI. The identified themes were refined and operationalised into statements
corresponding to each theme. The study was granted ethics approval by the Human Research
Ethics Committee at UNDA (Appendix 6). Participant information sheet (Appendix 7),
consent form (Appendix 7) and a draft set of statements for the CI (Appendix 9) were
individually sent to recruited participants and the researcher ensured that the signed consent
forms were received prior to the scheduled interviews.
CI is a method where items and contents and response processes can be assessed and
validated (Ryan et al., 2012). For this study, CI was conducted through the concurrent thinkaloud (CTA) procedure, a method that provides an opportunity for the respondents to speak
aloud about their thoughts (Charters, 2003). The role of the interviewer is predominately to
listen to the respondents while respondents are encouraged to speak aloud their thought
process either as they answer each question or after they complete the task. Unlike qualitative

29
interviews which aim to identify the meaning of a phenomenon (Evans, 2017), the distinctive
characteristic of CI is that it aids to identify tool items where respondent interpretation and
the developer’s intentions are asymmetrical and to identify ways in which those items can be
modified based on the responses given (Charters, 2003; Peterson et al., 2017).

The CI process entails determining item intent, collecting data, analysing it, and
comparing respondent interpretation to the original meaning (Castillo-Díaz & Padilla, 2013).
It is to note that a process of defining the construct, identifying the measurement scale, and
developing items are required in the early stages. CI expands on this by utilising these
connections to determine item intent (Fortune-Greeley et al., 2009; Ryan et al., 2012). Item
intent is directly related to the aspect of the construct that the item is intended to leverage
(Dumas et al., 2008). Importantly, before the CI Phase, the scale developer/s should
document the intent of each item. The interpretations of item intent and the corresponding
scale construct serve as a foundation for determining whether there is a mismatch between
respondents' interpretations and responses and interprets the item and what it is designed to
measure (Knafl et al., 2007; Peterson et al., 2017).
As the outcomes collected in Phase One led to the development of Phase Two, the
researcher conducted an extensive literature review to understand the similarities and
differences between the concepts of QOL, HRQOL, well-being and patient satisfaction. This
was conducted to ensure that refinement of the tool and its items was conducted consistently.
In addition, the CTA procedure allowed the researcher to recognise the issues and errors both
with item comprehension and with the overall questionnaire structure. The in-depth and rich
information collected through the CTA procedure also allowed the researcher to identify and
determine some additional HRQOL items.

Chapter summary
In summary, this chapter addressed the initial stages in the development of an OCspecific HRQOL PROM tool using patient involvement. The chapter detailed the qualitative
approaches used in the development of a HRQOL PROM tool that captures the ‘patient
voice’ through a grass-roots approach. Each method served a unique purpose for the tool
development. The qualitative techniques employed in this thesis included:
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•

Phase One: Community conversation as a preliminary work, followed by semistructured telephone interviews and focus groups.
Purpose: To gather baseline evidence for the later creation of a PROM that defines
HRQOL for women diagnosed with OC.

•

Phase Two: Utilisation of CI through CTA procedure.
Purpose: To refine and validate the items collected from the preceding qualitative
dataset.

The following two chapters detail the sequential phases in the format of journal
articles that have been submitted to Patient Related Outcome Measures. The first article has
been accepted for publication and the second article has received comments from the first
reviewer. These chapters provide a detailed description of the data collected and analysed
using respective qualitative methods.

39

Chapter Four: Results (Phase One)
Women diagnosed with ovarian cancer: Patient and carer
experiences and perspectives

The following manuscript has been accepted by Patient Related Outcome Measures on 15
December 2020 and is formatted according to their Instructions for Authors.
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Introduction
This chapter explores the processes associated with the initial stage of a patient led
development of HRQOL PROM. The purpose of this qualitative phase is to seek and hear
“patient voice” and to identify the patient views of the health symptoms and outcomes that
matter most to them as they traverse their disease pathway. While the following information
has been presented in the format of a journal article, the contents describe all aspects, from
the recruitment process to data analysis and interpretation, with the identification of the study
limitations.

This manuscript was submitted to and accepted by the journal Patient Related
Outcome Measures. The format therefore follows the journal requirements and has completed
two rounds of blind peer review.
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Abstract
Purpose: By directly engaging with women diagnosed with ovarian cancer, this study aimed
to explore and identify their view of the health symptoms and outcomes that matter most to
them as they traverse their disease pathway.
Background: Patient reported outcome measures in ovarian cancer have tended to focus on
physical symptoms rather than the more complex psychosocial aspects of living with the
disease. Using a ‘ground-up approach’, this study sought to comprehensively understand the
health concerns that matter most to women with ovarian cancer as a first step in generating
items for development into an ovarian cancer specific patient reported outcome measure.
Patients and methods: Following an extensive literature review, we sought to capture the
“patient voice” through a qualitative descriptive approach including a community
conversation with ovarian cancer patients, their carers and clinicians, and interviews and
focus groups with women with ovarian cancer. Thirteen women were interviewed
individually, and two focus groups were conducted. A template thematic analysis was used to
analyze the data.
Results: Key themes included challenges related to clinical diagnosis, treatment phase,
altered relationships with family/friends, financial issues, relationships with health
professionals and coping strategies. Within each key theme, several sub themes emerged that
were identified as various challenges experienced by participants. Diagnostic delay,
chemotherapy and surgery-related challenges, negative impact of sexual well-being on
partner relationship, communicational challenges with health professionals were among the
few issues identified. In addition, self-empowerment was identified as a coping mechanism
among participants.
Conclusions: By identifying priorities for women diagnosed with ovarian cancer we have
highlighted the need for strategies to reduce diagnostic delays and improve quality of life for
these women. Data will inform the development of an ovarian cancer specific patient
reported outcome measure.

Keywords: Focus Groups; Health-Related Quality of Life; Qualitative Descriptive; PatientReported Outcome Measures; Semi-Structured Interviews
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Introduction
Ovarian cancer (OC) affects women of all ages but is most commonly diagnosed after
menopause. More than 75% of affected women are diagnosed at an advanced stage because
early-stage disease is usually asymptomatic, and symptoms of late-stage disease are
nonspecific. The strongest risk factors are advancing age and family history of ovarian and
breast cancer.1 Currently there is no effective population-level screening test for OC.2,3
Treatment usually involves radical surgery and chemotherapy with subsequent lines of
chemotherapy for disease recurrence.4 Treatments can impair health-related quality of life
(HRQOL), a concept that pertains to general well-being or outcomes surrounding a specific
disease.5,6

Over the previous two decades, patients have had increasing roles in providing information
and participating in clinical decisions for managing their cancer. Structured patient provided
information without clinician modification and/or interpretation is termed a patient-reported
outcome measure (PROM).7 PROMs can be either generic tools such as the hospital anxiety
and depression scale or disease specific tools designed for specific groups of patients such as
those with gynecologic cancers.8 Patient involvement has a profound impact on PROM
development as it is only the patients who can determine item relevance and
comprehensibility of the tool.9,10

Currently, four validated OC specific PROMs have been developed to measure HRQOL of
the patients: The European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire of Cancer Patients - Ovarian Cancer module (EORTC QLQ-OV28),
Functional Assessment of Cancer Therapy Ovarian Cancer (FACT-O), FACT Ovarian
Symptom Index (FOSI) and Measure of Ovarian Symptoms and Treatment Concerns
(MOST).11-13 However, these tools do not identify all aspects of HRQOL and differences
exist in the level of patient involvement in the development of these PROMs, which is vital
for PROM development.14

This study is affiliated with an overarching project, Patients First: Continuous Improvement
in Care-Cancer (‘CIC’ Cancer), that aims to develop an OC PROM to measure HRQOL,
through a ‘ground-up approach’ that includes meaningful patient involvement. As an initial
step, this phase of the study involved the collection and analysis of qualitative data to inform
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the subsequent generation of items necessary for the development of an ovarian cancer
specific HRQOL tool.
Material and Methods

Study design
Based on an extensive literature review and assessment of the content of existing cancer
PROMs, this study utilized a qualitative descriptive approach. A qualitative descriptive
approach enables the researcher to obtain comprehensive details of personal events as
experienced by individuals, and is appropriate for health science researchers as it provides
rich and descriptive information from the participant’s perspective.15 This study employed a
community conversation for women with OC, their carers and a clinician (PAC) to shape the
subsequent semi-structured interviews and focus groups.

Participants
Purposive sampling (non-probability) using a maximum variation sampling strategy was used
to identify participants. Purposive sampling enables the researcher to intentionally select
participants who have in depth personal knowledge of the topic which will contribute to the
study in alignment with the research aims.16 The participant inclusion criteria were women
diagnosed with OC aged above 18 years, who were living in Western Australia and fluent in
English. Carers of participants were also invited to participate in the study. Participants were
recruited at various time-points from their diagnosis.17

Recruitment procedure
Community conversation, interview and focus group participants were recruited through an
advertisement distributed through the media and relevant agencies including Cancer Council
Western Australia (CCWA) and Ovarian Cancer Australia (OCA). Interested participants
were asked to contact the researcher(s) and/or CCWA & OCA directly. Thereafter, the
participants were contacted by the researchers (CB, SB) who provided them with the choice
to participate in either interviews or focus groups. Details of date and time along with venue
for the community conversations, interviews and focus groups were sent out by e-mails to
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participants through both the CCWA member database and the OCA networks along with the
CCWA regional support coordinator. The initial “community conversation” facilitated by a
qualitative research expert (CB) was held with fifteen women with OC (different to those
who participated in the interview and focus groups), two consumer advocates and a
gynecologist with experience in gynecological oncology (PAC) to explore some of the key
issues of personal importance to key stakeholder groups.

Data collection
Ethics approval for this study was granted by the Human Research Ethics Committee at
University of Notre Dame Australia (018158F) and conforms to Australian ‘2018 Update of
the National Statement on Ethical Conduct in Human Research’. The participant information
sheet and consent form were provided to participants and the signed consent form was
obtained from the participants prior to data collection. All participants provided consent for
their de-identified data to be published. Guided by the literature review and the field notes
during community conversation, similar question format were formulated for both interviews
and focus groups, Figure 1. In addition, our study processes complied with the Declaration of
Helsinki.
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Q1

• If you think of your treatment and those days when you may have had issues with physical symptoms and side
effects, what were those that you were most affected by? Was there anything that particularly helped you cope
with these?

Q2

• Thinking now of the time from your diagnosis, was there anything that particularly worried you or caused you
some concern? If so, how did you try and seek help or have those concerns heard (by significant others / by
health care system)?

Q3

• Some others who have been through the same illness as you have talked about changes in relationships. Do
you feel that there were any changes to your relationships with (i) family (ii) friends? In what ways? If no,
why do you say that?
• What about your relationship with a partner or spouse?

Q4

• Of course, some have had to deal with practical matters once diagnosed too (for example, finances and
medical bills although there will be others).
• Do you have any experiences you could share with us and how you might have handled these?

Q5

• How important is the advice that you receive from health professionals – such as doctors and nursing staff?
Explore specialist and GP differences in supportive roles. Why / why not is this advice important to you?

• What would you say are your main sources of strength? / what helps you to cope?
Q6

• Any other issues we haven’t touched on today?
Q7

Figure 1 Question format used during semi-structured telephone interviews and focus groups.

Along with the qualitative research expert, the student researcher (SB) independently
conducted individual telephone interviews of approximately 30 minutes duration with
thirteen OC patients at their place of convenience. The research team (CB, SB) then
conducted two focus groups in metropolitan Perth, Western Australia. A total of 13
participants attended one of the two focus groups, each lasting approximately 90 minutes,
with participation of three carers in the second focus group. Participants varied in their age.
Most participants were employed and were married/defacto. Four participants were over five
years since diagnosis, but one participant had received a diagnosis less than six months at
time of the interview. Disease status of the participants at the time of the interview was
obtained. Six participants were undergoing active treatment, with a completion of at least two
full cycles of chemotherapy. The remaining participants confirmed that they were in
remission or awaiting treatment. The number of cases of OC in Western Australia is small
compared to some other cancers (e.g. breast, prostate) and it was important to recruit as many
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women with OC across the disease trajectory as possible. Thus, the focus of this study was
the importance of the different experiences of the participants.

Analysis
Data saturation was achieved and collected data was audio-recorded and transcribed verbatim
by the student researcher (SB). Template thematic analysis was performed which included
open and axial coding using the qualitative data management program, QSR NVivo (version
12), Figure 2.18 Template analysis is defined as a method for identifying, analysing19 and
reporting themes in the data based on the task question format. It enables the researcher to
identify emerging themes in understanding a phenomenon or event.20,21 Key themes
identified were categorized as core themes and further emerging themes then became the
categorical sub themes for analysis.

Figure 2 Stages of qualitative analysis process: An illustration.

Member checking also included sending the summary of coding and themes back to four
participants who had indicated that they were willing to receive this summary via the CCWA
and OCA support group coordinators.

Results
Six key themes emerged regarding various aspects of illness and treatment experiences
described by the women and their carers (Figure 3). Within each key theme, several sub
themes and relative sub themes emerged that were identified as various challenges
experienced by participants as detailed below.
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Figure 3 Representation of key themes emerged from interviews and focus groups.

Diagnosis, treatment and related issues
Four factors were identified in relation to the symptomatic presentation pertaining to the
disease and are shown in Table 1. Participants experienced pre-diagnostic symptoms
including abdominal/bowel discomfort and pain, urinary urgency, fatigue, weight gain,
abnormal menstrual bleeding and/or menopausal symptoms. Lack of awareness of disease
symptoms by both patients and health professionals (HPs) was a related issue. Due to work
and family commitments, several participants intentionally ignored their symptoms. In
further, majority of the participants expressed diagnostic delay as another challenge faced
during their clinical diagnosis phase.
Table 1 Percentage of participants with symptoms and presentation
Symptoms
Percentage of participants
Abdominal discomfort
19.2
Bloating
11.5
Bowel movement pain
7.7
Constipation
3.8
Eye issues
3.8
Fatigue
7.7
Joint pain
3.8
Menopause symptoms
11.5
Perineal pain
3.8
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Urinary urgency
19.2
Weight gain
7.7
Symptom presentation
Lack of disease symptoms awareness
42.3
Asymptomatic presentation
19.2
Self-monitoring of symptoms
7.7
Note: The percentage for each symptom/symptom presentation is calculated as per the
number of interview/focus groups participants reporting it. Thus, for total number of
participants (n=26), the total percentage of symptoms/symptom presentation does not equate
to 100 percentage.
Challenges related to receiving treatments were highlighted with at least half of the
participants feeling vulnerable at times since receiving their diagnosis. Most of the
participants were challenged by side-effects. Fatigue, nausea, neuropathy, memory loss and
loss of appetite were the most common side-effects identified, with less common side-effects
such as mucositis and organ failure also described. Support of family and friends provided
strength for the majority of the participants. Some women indicated having to modify their
usual diet, lifestyle and physical activity during treatment. Activities such as meditation,
cycling, gardening and yoga helped them cope during and after treatment. However, some
participants also mentioned how empowering themselves during treatment was vital.
Maintaining and having a relaxed mind, a positive attitude and a sense of humor were
practiced by a few, despite the situations they were facing at that time.

Another participant spoke of how she had lost the chance of experiencing motherhood.
Rurally located participants faced further travel challenges of time and distance. And
furthermore, two participants highlighted issues around having lack of treatment
options while travelling, either it be a rural destination or an interstate travel.

Living with the OC trajectory
Other key themes related to living with a diagnosis of OC across the disease trajectory.

Relationships and support.
All participants agreed that relationships with their family and friends influenced their lives.
Some participants spoke of experiencing lack of support with unpredictable reactions and
withdrawal of family and/or friends. Other participants spoke of being avoided and noticed
that people around them “react differently” which then created emotional reactions such as
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upset and insecurity. Furthermore, sexual relations and a changed level of intimacy with a
partner/spouse were identified as an important subtheme in their lives. Many participants
described how a lack of intimacy had put pressure on their partner/spouse relationship and
affected their emotional well-being. A few participants described their sexual relationship as
‘non-existent’ and that a counsellor had been consulted.

Most of the participants agreed and acknowledged having support from family and/or friends
had a profound impact on their lives. A positive relationship with close family boosted their
journey particularly following the diagnosis and during treatment. Participants described
drawing strength and emotional support, and an increased interpersonal relationship bond with
family and friends.

Financial issues.
Almost all participants reported having financial issues such as out-of-pocket expenses for
scans, surgery and other practical issues including hospital parking and medication costs.
Several participants reported lack of information about accessing health services. Some
mentioned the financial toxicity associated with their illness and that they lacked knowledge
of how to access support services such as paying the bills without going into debt and having
to access their superannuation funds for urgent and necessary expenses.
“I guess it was not even initially when I wasn’t told about certain things I could
access like my super. I had to find out I think two years down the track or
something. So it wasn’t, nobody even gave me that sort of information”.

Some participants had to stop work during treatment and others had to reduce their workload
to cope with the challenges and issues faced during their clinical journey.

Interaction with Health Professionals.
Participants spoke of their relationships and experiences with their respective HPs. In
general, most participants acknowledged having a positive relation with HPs including
general practitioners (GPs), gynecological oncology and medical oncology providers in terms
of the support and medical treatment provided to them. The advice received by the oncology
team was described by one participant as “absolutely phenomenal…(they) answered any
questions with patience and understanding”.
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Meanwhile, some participants spoke of a perceived negative relationship with their HPs.
Overall, many participants felt there were communication gaps in the healthcare system,
particularly during treatment, and participants experienced various forms of communication
challenges either with or between oncologists and GPs and specialist departments.
“Because of my complex medical problem, I’ve been out for a few months
affected by surgery and by several treatments. So, I found that (hospital’s)
communication between the different departments just wasn’t there”.

Furthermore, issues around clinician lack of empathy and compassion, and providing
inconsistent information about prognosis negatively impacted the emotional well-being of
many participants. A majority had a less than satisfactory relationship with GPs. Half of the
participants described the excessive length of time for their symptoms to be investigated
leading to a delay in their diagnosis. Some perceived being ignored or that GPs were “pretty
dismissive” about their symptoms thinking they were due to a urinary tract infection or
perimenopause and no further action was taken. Furthermore, participants mentioned having
difficulties requesting tests such as ultrasound scans and pressed for these.

Insufficient provision of information was one of the key issues in relation to treatment and
participants complained that oncologists, did not fully explain the side effects of the
prescribed medications. Some participants also reported a lack of involvement in decisions
about their treatment and not being provided with treatment options including at disease
recurrence.

Coping strategies.
Participants were asked to share their experiences on how they coped with difficult situations
through their clinical journey. They described support from family and friends, lifestyle and
physical activity assisted them to cope with difficult situations and kept them moving
forward. Walking, listening to music, meditation, nutrition and crafts were some examples.
Two participants mentioned how making time for themselves was important for both their
mind and body. Several participants sought help from support group organisations through
which telephone support services, information booklets and complementary services such as
yoga were provided.
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Self-Empowerment
Some participants emphasized that taking control of their own lives was their one main
strengths. Identified factors were being able to look forward, having an attitude of not giving
up and learning how to ‘stick up’ for oneself. Participants expressed that by being
independent and knowing their innermost selves provided them motivation and strength
throughout their lives. In addition, providing self-encouragement through positive attitude
and feeling gratitude helped them.
“I do need and want to practice gratitude every day. I am grateful for what I’ve
got. And I’m much more in tune with the little things in life”.

Further to this, having a strong spiritual belief system helped to calm them and became a
source of comfort explicitly during chemotherapy. In addition, having spiritual belief helped
not only the participants, but also their families to gain strength in order to cope with difficult
situations.

Discussion
In this study women with OC were able to express their own voices based on their individual
experiences. Therefore, the six themes identified describe both HRQOL and contextual
themes. Post diagnosis and treatment-related issues, relationships and supports with family
and friends, financial issues, relationships with healthcare providers and self-perceived
coping strategies were the key themes identified. Each theme had a number of overlapping
sub themes that were identified as priorities for the women. In particular, challenges related
to relationships, financial issues, relationships with healthcare providers and coping strategies
were experienced during and after diagnosis and treatment.

Diagnostic delay was a key concern and our data suggested that lack of early symptom
awareness due to insufficient OC knowledge and symptom recognition by participants and
HPs contributed to the delay. This is consistent with studies that have low levels of OC
symptom awareness are associated with delayed diagnosis.22-24 While, lack of cancer
detection and inexpedient referral patterns influenced incorrect diagnosis by the physicians,25
and greater public education to increase knowledge of disease symptoms could be
helpful.26,27
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Most participants received a combination of surgery and chemotherapy. Treatments adversely
affected physical well-being with prevalent symptoms such as fatigue, nausea and
neuropathy. Research is now focusing on symptom management interventions guided by the
implementation of PROMs into clinical settings and trials.5,28,29 Several surgery-related
outcomes including change in body image, premature and sudden onset of menopause, and
loss of reproductive function may affect psychological well-being.30 The possible loss of
fertility during treatment with cancer can be more distressing than cancer itself, according to
recent reports where efforts to maintain fertility through techniques such as fertility-sparing
surgery are essential in younger women diagnosed with gynecological cancers as they could
lead to an improvement in quality of life.31 Another recent study indicated high levels of
psychological distress when diagnosed women reach childbearing age as menstrual function
and fertility were lost. It is therefore important to monitor the progression of cancer but
should also provide appropriate fertility preservation counselling. This has potential to
alleviate stress, anxiety and depression and a smaller negative effect on the quality of life. 32
Consistent with our findings, a past study showed that those who underwent surgery have
experienced psychological distress such as lack of self-esteem, self-worth and loss of
femininity.33,34

Survivorship is important in cancer care and recent improvements in treatment have resulted
in an increased number of survivors.35 However, our findings highlighted the need for
patient-centered care. Patient involvement is vital in clinical care, where a recent study
pointed to the significance of patient-clinician communication. This communication style
provides patients with the platform to raise and discuss issues with clinicians thereby shaping
subsequent clinical care processes and outcomes.36

One of the contextual themes of HRQOL identified was perceived lack of provision of
adequate information and services. Studies show that educating and communicating patients
and their families regarding treatment options and its underlying side-effects will prepare
patients to realize the likely outcome of treatment and will assist them in facing upcoming
challenges.30,37 Inadequate services such as counselling were identified. Studies show that
psychological and other supports are essential in these women’s lives, focusing on
psychological well-being as well as counselling related to financial and nutritional needs.30,38
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Further, our findings illustrated some communication gaps between the women and their
healthcare providers. Research shows that engagement of patients with their healthcare team
strengthens and increases the provision of patient-centered care and thus potentially aids
cancer control.39 A 2013 study described that patient-clinician communication may assist
adherence and agreement to treatment, where for example, two-way communication on
treatment-based symptoms could aid in symptom management.40 A recent study which
focused on the sexual function of women diagnosed with OC reported that not only was there
a communication gap between patient and clinicians, the clinicians expected patients to have
disease related sexual problems and waited until patients spoke about their concerns.41
Improving survival, functional recovery and quality of life while minimizing long term sideeffects are key priorities in cancer care.

Social well-being is consistent with the concept of HRQOL. The importance of being
supported by family and friends, especially partners/spouses, was a critical factor for wellbeing. Some participants experienced changes in their relationships. Time spent with family
was reduced due to treatment demands and withdrawal of loved ones from them. Previous
studies have reported that women have felt displeasure from their friends and were unwilling
to discuss about the disease.37

Overall, participants experienced highly compromised HRQOL, around the time of diagnosis
and during treatment. There is an urgent need to develop new strategies for early detection
and screening,3 as diagnostic delay was associated with psychological distress such as
anxiety, fear of death, parental stress and uncertainty in the current study and has also been
previously reported.37 Additionally, participants experienced challenge in obtaining
appropriate information to access and benefit from the healthcare system post diagnosis.
Multiple studies have found that unreliable provision of knowledge and information is a
driver of poor medical care in many high-income countries, including Australia.42
Involvement of patients in decision making and public engagement could improve the
evidence based value of their healthcare.43

Emotional domain is another aspect of HRQOL. Emotional distress was experienced
particularly during treatment phase. Fear of recurrence was a source of emotional distress.
Previous studies related to gynecological and OC research shows that women have fear of
disease recurrence during the treatment and post treatment phases and that these fears are
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poorly understood.44,45 Frustration was also of concern with almost all women frustrated due
to their treatment side-effects and symptoms. A 2020 qualitative study that investigated life
experiences of women diagnosed with OC found similar results on how women fall into
frustration following treatment completion.46

Understanding and measuring HRQOL outcomes related to the sexual well-being of women
diagnosed with OC is vital. Half of participants had poorer sexual function impacting their
overall health and well-being. Changes to body image, sudden onset of menopause, infertility
and lack of intimacy were identified and negatively impact emotional well-being with a sense
of losing feminine identity. It has also been found that difficulties with body image and lack
of intimacy are associated with impaired quality of life.41

Not only do individuals diagnosed with cancer have detrimental impacts on their sexual
functioning, it often influences their partners. Studies suggest that cancer partners may suffer
equal or even higher levels of distress relative to their sick spouses. Partners of cancer
survivors do not often have the resources to offer sufficient care to their female partners.47
Findings from a 2009 study indicate that the sexual perceptions of the partners were
influenced by loss of interest in the individual with cancer and tension and fatigue correlated
with care tasks. Carers agreed that reduced happiness with the partnership could be followed
by poorer quality of life as well as higher levels of anxiety and depression.48

Financial aspects were described, and this influenced participant wellbeing. Due to the
amount of time required to spend in treatments, some participants had lost their income
stability either due to change to their employment status or being unable to continue in the
workforce, impairing their emotional well-being and overall HRQOL.49 Some issues might
appear to be more minor, such as related to the lack of car parking availability at respective
clinical settings, but when needed on multiple occasions, this was a more major concern.
Studies in women with OC found that disease and treatment related burdens create several
issues including social and financial effects on their lives.38,50

Participants also described current strategies they used in daily life. Participants utilized
numerous coping strategies such as modified diet and lifestyle, which could be considered as
a contextual factor that could influence HRQOL. Family and friend support was another
major help sought by these women, which in turn helped improve and maintain their quality
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of life.51 Self-empowerment techniques such as ability to look to the future, having positive
attitude and sense of humor were a few techniques employed by the participants. Recent
studies also show similar coping strategies used by women and how changed views and
adding humor to their personal experiences was a means of self-healing.52,53 Overall, the
participants were able to maintain their HRQOL and continue a modified normal life with the
implementation of various strategies and self-management techniques into their lives.54

Limitations and strengths of this study
There are approximately 115 new diagnoses of OC per year in Western Australia,55
potentially compromising data collection using a small sample size. However, maximum
variability and data saturation were achieved using small sample size56 and thus should not be
considered as a limitation but a strength. While the study sought to explore patient outcomes
across the clinical trajectory, participants might not have accurately recalled their
perspectives, constituting to another limitation.
Moreover, rich and descriptive data were obtained using the qualitative methods57 where
intentionality of the participants and their carers were explored. In addition, utilizing a
qualitative approach has enabled a holistic understanding of patients’ and carers’ lived
experiences. The ‘bottom up’ approach of involving patients from commencement and
throughout the study will ensure that going forward, priorities are clearly identified by the
consumers (women with OC themselves) in consultation with clinicians. We envisage that
the proposed OC specific PROM to be developed in a future study would be used in clinical
settings to identify and measure specific problems that patients encounter that needed to be
discussed.

Conclusion
By identifying key priorities for women with OC using a ‘ground-up community based
approach’, we have highlighted the need for strategies to reduce diagnostic delays, assist
patients in navigating the healthcare system, and improve their HRQOL and potentially
develop a OC specific PROM that will enable better identification and earlier treatment of
symptoms during the entire course of the disease.
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Chapter summary
As this study aimed to develop an OC-specific tool though ‘grass-roots’ or ‘groundup’ approach, the qualitative methods have captured rich information from patients’
perspective and the qualitative analysis conducted has gathered baseline data for the later
creation of a PROM that defines HRQOL for women diagnosed with OC. Through semistructured interviews and focus groups, we sought to gain a comprehensive understanding of
their health concerns at a personal level as the first step in identifying the specific items for a
new HR-QOL measure.

Further, the lived experience, as described by the participants, included data
identifying various qualitative variables. As an initial developmental stage, identifying and
reporting on processes and outcomes from qualitative data is also important. We also believe
that by documenting the perspectives of women with OC that extend beyond symptomology
and clinical outcomes that we provide an insight into the key priority areas for the women in
terms of better managing their illness.

The six major themes identified in this study forms the domains of the measure that
are yet to be developed in the next phase, Phase Two. Through the implementation of CI, the
subsequent phase is elaborated in the following chapter.
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Chapter Five: Results (Phase Two)
Employing cognitive interviewing to evaluate, improve and
validate items for measuring the health-related quality of life of
women diagnosed with ovarian cancer

Submission of work to Patient Related Outcome Measures on 24 November 2020, whereby
the first peer reviewer report has been returned.
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Introduction
This chapter describes the refinement and validation of the wording of the items
developed from the qualitative information collected in the preceding study phase (provide
chapter number here in the brackets). This chapter reports the ways in which the CI technique
enables to mould the items into statements that can be integrated into a disease-specific
PROM through the participation of women diagnosed with OC. In addition, the study also
highlights the purpose of employing CI in qualitative research.

The following manuscript is submitted to Patient Related Outcome Measures on 24
November 2020, whereby the first peer reviewer report has been returned. The manuscript
has been assembled in a journal article format, by detailing the qualitative approach used.
This chapter also illustrates the need to further validate the tool to perform further research
studies in field tests and to confirm its psychometric properties.
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Abstract
Purpose: This study investigated the content validity of items for inclusion in a new healthrelated quality of life measure suitable for patients with ovarian cancer.
Background: Patient-reported outcome are self-reports of patients by using tools and/or
instruments called patient-reported outcome measures. Use of patient-reported outcome
measures in clinical settings facilitate the delivery of better health care to improve patient
health outcomes.
Patients and Methods: This study used cognitive interviewing techniques with fourteen
women diagnosed with ovarian cancer and at different times since diagnosis, to evaluate
items derived from a previously collected qualitative dataset. A set of draft items was
administered via telephone, Zoom and WhatsApp app together with questions on item
meaning and wording. Interviews were transcribed and thematically analysed.
Results: Four broad themes emerged in relation to the questionnaire construct and
comprehension of items: intent and clarity, wording, relevance and context, and overall
questionnaire construct. All draft items were adjusted based on the interview findings. The
final set of 38 health-related quality of life items comprised 7 items describing physical
health and functioning, 21 describing emotional wellbeing and 10 items describing social
wellbeing; each rated on a five-point frequency response scale.
Conclusion: The items reflected a range of personal experiences associated with the patient
clinical journey, creating a health-related quality of life tool specific to women diagnosed
with ovarian cancer. The cognitive interviewing process established content validity for the
tool, thereby, preparing it for field testing and evaluation of its psychometric properties. This
study highlighted the fundamental role of cognitive interviewing during health-related quality
of life questionnaire development to ensure that item content is grounded in patient feelings,
functioning and meaning.
Keywords: Cognitive interviewing; Health-related quality of life; Ovarian cancer; Patient
reported outcome measures
Introduction
Ovarian cancer (OC) is the most lethal gynaecological malignancy. Globally, 230 000 women
are diagnosed with OC and 150 000 die of the disease each year.1 In Australia, OC is the
eighth most commonly diagnosed cancer among women with approximately 1500 new cases
diagnosed every year and a five-year relative survival of only 46%.2 OC survivors remain at
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high risk of relapse and fear of cancer recurrence which may lead to significant anxiety and
psychological morbidity.3 Many OC survivors report moderate to severe symptoms such as
peripheral neuropathy and fatigue two years after completing treatment, and may experience
a disease recurrence, or developing a new primary cancer, all of which can influence healthrelated quality of life (HRQOL).4,5
Patient reported outcomes are defined as “any report of the status of a patient’s health
condition that comes directly from the patient, without interpretation of the patient’s response
by a clinician or anyone else”.6,7 Patient reported outcomes are collected using tools and/or
instruments called patient reported outcome measures (PROMs).8 Incorporating PROMs into
clinical settings is believed to enhance the delivery of health care9 and achievement of patient
health outcomes.10

Clinical trials involving cancer patients often utilize general PROMs, (for example, the Short
Form Survey 36 (SF-36)) and validated tools for specific cancer types, including
gynaecologic cancers.11 Whilst commonly used in research, PROMs are less often used in
routine clinical practice,9 and important information on functional recovery and HRQOL
could be missed.

The European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire for Cancer Patients (EORTC QLQ-C30) and Functional Assessment of
Chronic Illness Therapy Functional Assessment of Cancer Therapy - General (FACIT FACTG) are the two most widely used cancer-specific HRQOL questionnaires and can be
augmented by site- and/or treatment-specific modules.11 Both EORTC and FACIT have OCspecific modules including EORTC QLQ-OV28, FACT-O and FACT-ovarian cancer
symptom index (FOSI).12 The EORTC QLQ-C30 questionnaire contains 30 items which
assess functioning, global HRQOL, and cancer-related symptoms. It is complemented by a
OC module, QLQ-OV28, which contains a further 28 items including body image,
abdominal/gastrointestinal symptoms, hormonal/menopausal symptoms.13 The FACT-O
questionnaire comprises 27 items from FACT-G to cover four core domains of wellbeing
with an additional 12 items specific to OC. The FOSI is a shorter, more focused subset of the
FACT-O items that includes three subscales: disease/treatment-related symptoms and general
function/wellbeing.14 More recently, King et al developed a tool, the Measure of Ovarian
Symptoms and Treatment concerns (MOST), to assess patient-reported symptom burden as
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24

items

including

abdominal/disease/treatment-related symptoms, psychological symptoms and MOST-Wellbeing.15

Whilst each of these tools seek to describe experiences of women with OC, each were
developed using different methodological approaches and this could explain variations in
their content.16 For example, the FACT-O was developed to assess symptoms and quality of
life and semi-structured interviews were conducted with five health professionals (nurses)
and 17 OC patients with varying disease severity. Items were then reviewed by a panel of
experts.17 Additional to symptoms, the items reflect psychosocial aspects such as “appearance
of my body,” “able to feel like a woman”.17 Like FACT-O, the QLQ-OV28 focused on
measuring symptoms, both general and disease specific symptoms. Unlike MOST which
primarily focused on symptom benefit in women with symptomatic OC, neither QLQ-OV28
nor the FACT-O were specifically developed and validated in patients with platinum resistant
recurrent OC, where the aim of treatment is symptom benefit and palliation. Similarly,
differences exist in the level and stage of patient involvement in the development of
PROMs.13,14 The importance of this is seen in the work of Kirwan18,19 and illustrated by
Friedlander who showed clear differences between the level of important of symptoms
reported by symptom benefit in women with symptomatic OC.

We previously conducted semi-structed interviews and focus groups with women with OC
and identified key experiences and priorities for women diagnosed with OC. Findings
included challenges related to diagnosis and treatment, adjustments in their relationships with
family and/or friends, financial issues, some difficulties in their relationships with health
professionals and comment on useful coping strategies. Through the use of template thematic
analysis, these findings were further developed into a set of items that could be useful for the
development of a values-based OC PROM (under review).

Establishing content validity is a fundamental first step in establishing whether an outcome
measure is fit for purpose.20 Using cognitive interviewing (CI), the purpose of this study was
to refine, and content validate the items/statements derived from the qualitative data collected
in our previous study. We also aimed to examine whether additional items from the dataset
could contribute to a broader questionnaire on factors related to HRQOL.
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Material and Methods
This study employed cognitive interviewing (CI) with the integration of concurrent thinkaloud (CTA) procedure. CI is a method whereby items and contents and response processes
can be assessed and validated,21 ensuring the content clarity and relevance of the items and
response categories.22,23 The CTA procedure is a research method in which respondents speak
aloud about their thoughts as they complete each questionnaire item in regard to personal
understanding of the items.24,25 Thus, this interview procedure was implemented to identify
items where respondent interpretation and the developer’s intentions were dissimilar and to
identify ways in which those items can be modified based on the responses given.22,24 This
study was granted ethics approval by the Human Research Ethics Committee at University of
Notre Dame Australia (UNDA) (2020-010F) and our study complied with the Declaration of
Helsinki.

Recruitment procedures and study population
Our previous study incorporated input and guidance from relevant community support
organisations, primarily Ovarian Cancer Australia (OCA) and Cancer Council Western
Australia (CCWA). This study also worked in partnership with CCWA, OCA and the
Australia New Zealand Gynaecological Oncology Group-Survivors Teaching Students, in
recruiting participants through advertisements distributed through the media and relevant
agencies. The recruitment process was slow as it coincided with the COVID-19 pandemic.
Additional participants were recruited through King Edward Memorial Hospital and Solaris
Cancer Care, a patient support organisation, in Perth, Western Australia. All participants who
expressed interest in participating in the study were contacted directly by the UNDA
researcher (SB) to schedule an interview at a mutually convenient time.

Recruitment was purposive and utilized a maximum variation strategy, aiming to represent
variation in the stage of OC, treatment received, demographic and socioeconomic
characteristics. This sampling technique provides insights and in-depth knowledge regarding
individuals’ experience in different circumstances.26 Participants were women diagnosed with
OC, older than 18 years and were proficient in English.

Data collection
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Participants were provided with all relevant documents including a consent form, participant
information sheet and interview schedule, and signed consent was received prior to interview
commencement. Due to the COVID-19 pandemic, interviews were conducted using
telephone or video (Zoom/Skype/WhatsApp App) according to the participant’s preference.
Identified statements from our previous qualitative study were tested by conducting CI using
the CTA procedure (Table 1). The focus of applying CTA was not limited to determining
certain words or response categories of the items but also to identify how and why
respondents answered each item. Prior to the interview, participants were briefed that they
would be asked to share their thoughts and opinions on the statements that were unclear or
difficult to comprehend (Charters, 2003). Participants were encouraged to engage with the
researcher by reacting to pieces of the document and explain if they found the items and/or
content confusing or unfamiliar.
Table 1: Probing questions used during the CTA procedure
Context
Question Format
HOW
How did you respond to that
statement?
WHY
Why did you respond in that
way?
REWORD
Is there any other way to
reword the statement?

Example
“How would you rate that
statement?”
“Why did you agree but not
strongly agree?”
“You were confused with
that statement. So, would
you reword that statement?”

Data Analysis
Collected data was audio-recorded and transcribed verbatim and was imported into QSR
NVivo version 12 for data management and analysis.27 In the last five interviews conducted,
no new codes or themes were generated and thus saturation of data was achieved. The CI data
were analysed in a multistep process. The initial analysis comprised open coding, with the
intention of establishing codes based on participant feedback and suggestions. Thereafter, a
second analysis involved axial coding to identify patterns in the codes for each item based on
participant feedback and to categorise it under broader themes. Data collected via the CTA
procedure were thematically analysed using this theme coding approach.28 Braun & Clarke
have defined thematic analysis as a method that aims to achieve an in-depth understanding of
the phenomenon and enable identification of emerging themes and patterns across the
qualitative data collected.29,30 Items generated from all interviews (including the initial patient
interviews) and the literature relating to coping with cancer were collated into the interview
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statements. Additional items were also generated based on emerging themes identified during
the CI data analysis. The identified themes were then refined and operationalised into
statements corresponding to each theme.

Investigative team
During multiple sittings, the supervisory team from clinical and research backgrounds,
reviewed the modified statements to establish a final set of items. A qualitative researcher
who had collaborated closely with community groups, a health researcher with research
expertise in qualitative study designs and had expertise in developing quality of life
measures, a health researcher whose expertise lies in the areas of health service redesign and
translation, a gynaecologist and a higher degree research student. Team meetings formed a
fundamental part of the questionnaire development phase. In compliance with all collective
feedback and suggestions, supervisory team meetings were held to determine necessary
changes and achieve a consensus on the modifications.
Results

Participants
Fourteen participants took part in individual telephone or video interviews with a mean
duration of one hour and fifteen minutes (range 30 minutes to one hour 50 minutes).
Interviews for one participant were completed over two occasions for their convenience, and
the initial interview which provided pilot data was also incorporated into the dataset.
Feedback collected from the pilot interview informed modification of the statements’
response scale to be used in the subsequent interviews. Participants varied in age,
employment and marital status but all lived in a metropolitan setting. Seven participants had
been diagnosed over five years previously and two participants had received their diagnosis
within a year of the interview. Among the 14 interviewees, five participants were undergoing
active treatment because of recurrence of their cancer (Table 2).
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Table 2: Description of study participants (n=14)
Characteristics

No: of participants

Age Group (years)
50 to 59

5

60 to 69

5

70 to 79

4

Current Employment Status
Currently looking for work

1

Employed (Casual, Part-time, Full-time, Self-employed)

5

Home duties

1

Retired

7

Education
High school

5

TAFE certificate

4

University degree (undergraduate/postgraduate)

5

Employment Status before diagnosis
Employed (Casual, Part-time, Full-time, Self-employed)

10

Home duties

2

Retired

2

Marital Status
Married or de facto

8

Separate or Divorced

4

Single/Never married

1

Widowed

1

Treatment Status
Not on treatment

9

Currently on Treatment

5

Length of time since diagnosis
6 months – 1 year

2

2-4 years

5

>=5 years

7

Cancer Recurrence (yes)

5
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Draft questionnaire examined using CI and CTA
Draft items were classified into the domains identified in our previous qualitative study.
Diagnosis and Treatment-related (chemotherapy, surgery and complementary therapies),
relationships with family/friends, financial aspects, health services and interactions with
health professionals, and coping strategies. Challenges related to diagnosis and treatments
were documented. Key themes such as physical wellbeing, emotional wellbeing, relationships
with family/friends, health services and interactions with health professionals, and coping
strategies were identified as related to living with an OC diagnosis across the clinical journey.
A Likert response scale was created for the items.

The draft questionnaire acknowledged all data from the original qualitative study and
included a set of questions to collect participant demographic and cancer history information.
The next four sections focused on challenges related to diagnosis and treatment and included
skip questions which directed participants to appropriate sections based on the responses
given, with the response scale measuring the severity of challenges. The remaining sections
with items related to HRQOL, satisfaction with services and coping strategies were provided
with a response scale of frequency (Table 3).

Table 3: Total number of items per questionnaire section prior to modification based on CI
data
Items (n)
Demographics

10

Cancer History

5

Section 1: Clinical Diagnosis

4

Section 2: Chemotherapy

5

Section 3: Surgery

5

Section 4: Complementary Therapies

2

Section 5: Emotional Wellbeing

52

Section 6: Financial Wellbeing

10

Section 7: Health Services

15
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Section 8: Communicational & Informational Challenges

13

Section 9:
Seeking help & Coping Strategies

10

Resilience

15

Refinement of HRQOL items
A multistep analysis process was then used to classify how the items could be modified,
using four broad themes. Refinement of HRQOL items is illustrated with examples below.
Item intent and clarity.
Responses for several items were inconsistent with the item intent, failing to interpret the
researcher’s objectives. For some items, participants reported, “I do not understand what this
means” or “I couldn’t get to the meaning of the question”. For example, one original item
was “I felt frustrated during and/or after receiving a treatment”. A majority of the participants
comprehended “frustrated” in terms of the treatment received, but the researcher’s intent was
to measure “frustrated” in relation to a participant’s activities whilst undergoing treatment.
With participant input, the item was modified to “I felt frustrated that I could not take part in
usual activities during and/or after treatments”.
Item wording.
Difficulties with comprehension of the meaning of some items was identified. For instance,
the statement “I feel valued because I can still contribute to the workforce” created confusion
in the participant. One particular response was “I am not working, but I still feel valued. I
would put not applicable for that one. But I would put strongly disagree because I feel valued
because of work”. To better structure it, the item was modified to “I have felt valued because
of the work that I can do (home, workforce)”.

Other items were considered vague by participants and difficulties arose in communicating
the researcher’s intent of the items to the participants. For example, the item “My
family/friends have reacted unexpectedly to my illness” could have been interpreted as a
positive or negative experience. With participant feedback, the item was modified to “My
family/friends have reacted unexpectedly (in a negative way) to my illness”.
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Item relevance and context.
Some items had little relevance to participants’ age. These items included: “I have been
embarrassed by the way my body has changed” and “I have felt less feminine because of my
illness”. Moreover, several items specific to emotional wellbeing were not relevant to
participants who were under surveillance and not receiving treatment. For example, when
asked about “I have felt sick and unwell due to the side-effects of treatments I have
experienced”, participants replied saying “that’s hard because during the chemo, I felt unwell
and sick but since the chemo, I have had no problem”.

Finally, the complexities of some items made it difficult for participants to respond precisely.
For example, one original item was “My family/friends are generally supportive of me at this
time”. However, based on the participant’s perspective, the support received from family and
friends could have been different. Thus, the item was separated into two items. In particular,
one participant couldn’t comprehend the context of the item within the social domain.
Initially, the statement was developed as “I have felt isolated socially because of my illness.
The participant could not, however, answer in what context the word "socially" meant. The
item was subsequently changed to “I have found it difficult to connect socially with people
because of my illness (e.g. at work, in public)”.

Refinement of items describing contextual factors for HRQOL
The qualitative dataset contained additional themes of disease/treatment and financial issues,
communication with health professionals and coping strategies. These themes were
developed into three sets of questions that reflected contextual factors for HRQOL: patient
symptoms, satisfaction with health services and strategies for self-sufficiency and resilience.
These items were refined using the same multistep analysis process and examples are
presented below.
Item wording.
Some items related to technical terms that were complex to understand. For example,
concerns were raised on specific terminologies such as “cancer recurrence”, “mucositis”,
“full cycle of chemotherapy”, “complementary therapies”. In response, clear definitions were
constructed.
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Item relevance and context.
Relevance of specific items was age dependent. For instance, questions regarding “sudden
onset of menopause” and “inability to have children” had no impact on the wellbeing of
many participants because they had undergone menopause prior to receiving their OC
diagnosis. Thus, a “not applicable” response column was included to the patient symptom
section. Since there were items of little relevance across the questionnaire and upon joint
agreement amongst the supervisory team, a timeline was provided for every section.
The context of the item “There is a lack of financial assistance with practical support” was
unclear as one participant expressed, “I haven’t had to seek that out. So, I don’t really know. I
haven’t needed it but to listening other ladies I think there probably is a need for it”.
However, the researcher’s intent was to know whether the participants had any challenges
accessing the services or not. The item was modified as “There has been a lack of practical
support offered to me”. In addition, the item “I maintained a sense of gratitude” seemed out
of context to a participant. The item was modified to “I have maintained a sense of gratitude
for what I am able to do/achieve”.

Questionnaire construct
Some participants mentioned that the response format type for HRQOL and wellbeing items
could be improved as responses could have reflected upon frequency, rather than merely
agreeing/disagreeing to a statement. For instance, participants responded by using
expressions such as “at times” or “sometimes” and found it difficult to merely agree/disagree
to the items. Thus, a frequency format of Always/Often/Sometimes/Rarely/Never was applied
to sections that measured aspects of HRQOL and wellbeing.

In summary, the CI and CTA processes informed substantial item reconstruction to achieve
content validity for this participant group. The questionnaire in its entirety was restructured:
including 67 items which were modified, 10 items were condensed and merged into
appropriate sections, 66 items were deleted, and 15 items were added. The items describing
HRQOL were grouped, forming an HRQOL instrument named the OVArian cancer health
related Quality of Life (OVAQOL) scale. This scale comprises items that contributed
conceptually to three HRQOL domains: physical wellbeing (n=7), emotional wellbeing
(n=21) and social wellbeing (n=10.

The rich original qualitative dataset and the
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comprehensive interview and analysis processes informed the development of accompanying
sets of questions on demographic characteristics, disease and treatment status, patient
satisfaction with healthcare services and patient resilience (Table 4).
Table 4: Final structure and number of items in the questionnaire with examples of OVAQOL
items
Items (n)
Section 1: Demographics

14

Section 2: Disease and Treatment related symptoms

26

Section 3:

OVArian cancer health related Quality Of Life

(OVAQOL) scale

7

Physical Wellbeing
Example:“felt sick due to treatment side-effects”
“bothered by the symptoms”
“frustrated by not being able to exercise”
“difficult to care for my family and/or friends”

21

Emotional Wellbeing
Example:“afraid of cancer coming back”
“felt valued because of the work that I can do”
“felt less self-worth”
“worried about loss of income”

10

Social Wellbeing
Example:“difficult to understand carer’s/partner’s feelings”
“family has been generally supportive”
“found it difficult to connect socially with people”
“partner needed more self-time”
Section 4: Satisfaction with Health Services

11

Section 5: Resilience

22
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Discussion
Using a CI approach, the purpose of this study was to refine and validate the wording of the
items extracted from the data collected during a previous qualitative study. Four broad
themes of item adjustment emerged based on the feedback and suggestions provided by the
participants, and following modification and evaluation, evidence for the content validity of
the items was generated. Going forward, this new questionnaire has capacity to measure
outcomes in women with OC and contribute to improving their health outcomes across the
survivorship trajectory,31 and is ready for further validation.

Originally, the draft instrument consisted of 52 HRQOL items, and thereafter, has been
reduced to 38 items. Since the questionnaire seeks to measure disease and treatment specific
HRQOL outcomes of women diagnosed with OC, the items and its contents should reflect the
purpose of measuring HRQOL. HRQOL is a multidimensional construct that measures the
impact of a disease on physical, psychological and social relations aspects on a person’s life32
as defined by the World Health Organisation.33 Upon modification and evaluation, the items
were examined and categorised into physical/functional, emotional and social domains
consistent with this definition. The concept of HRQOL does not measure aspects such as job
or income security.34 Thus, items pertaining to accessing information in relation to financial
needs were included in the patient satisfaction section with health services, while an item that
measures psychological distress in relation to loss of income was merged with HRQOL
emotional domain.

Our study findings illustrate how disease/treatment related symptoms had substantial impacts
on the HRQOL of our study population, consistent with previous studies.35,36 As an aftermath
effect, these symptoms in turn affect the ability and capability to perform tasks either it be
usual activities or professional.37 Emergence of physical wellbeing constituted one of the
important HRQOL domain. Included statements pertained to both physical health and
functioning status of patients diagnosed with OC. The statements illustrated the impacts of
symptoms from the patient perspective. Items related to “fatigue” and “difficulty sleeping”
measure patient health while “participation in usual activities” focuses to measure patient
functional ability. Similar to our findings, other studies have also revealed that people with
chronic illness struggle with daily life tasks by being dependent on others38,39, revealing that
it is important to measure physical domain of HRQOL for patients with OC.
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Emotional wellbeing is a fundamental component of HRQOL instruments. Items including
“depression”, “anxiety”, “fear of recurrence” were included in OVAQOL. Inclusion of such
items enable evaluation of psychological distress experienced by women whether it be
disease and/or treatment related by how severely it has impacted their HRQOL. In addition, it
enables the researcher to identify whether such items impact other domains of HRQOL as
previous research shows that psychological distress is related to poor performance status.40

Social functioning is also an essential component of HRQOL, particularly in relation to
support provided by the family and friends which is emphasized in other similar qualitative
studies.41 In turn, social relations and mental wellbeing domains are interconnected. In a 2001
study of individuals with breast cancer, Kornblith and colleagues identified that women with
low levels of support either it be through family, friends or professional, had higher levels of
psychological distress throughout their clinical journey.42

The initial qualitative dataset included important information describing factors related to the
women’s HRQOL, including their satisfaction with health services, help-seeking throughout
their clinical journey and resilience. In a recent study, it was indicated that HRQOL for those
affected with systemic lupus erythematosus found a positive association between patient
health care satisfaction and health status, possibly due to supports in the physical, emotional
and social domains.34 Recent studies also show that there is a direct relationship between
resilience, life satisfaction and wellbeing on those living with chronic illness43-45 and
indicates the importance of measuring the impact of such variables on wellbeing and
HRQOL. Thus, opportunistically and based on our findings and supporting information from
various literature, relevant items associated with health services and informational challenges
were collected into a module of questions describing ‘satisfaction with health care services’.
Items that measured various coping strategies and resilience were collected into a ‘resilience’
module of questions to enable measurement of the self-empowerment and self-sufficiency
strategies used by women during these difficult times.

Based on the development processes, the researchers believe that the content of OVAQOL
truly reflected the consumer voice as was captured through the preceding qualitative study
and the current CI procedures, each with patient involvement. This had not been performed to
this extent in the development of existing OC HRQOL instruments suggesting limited patient
involvement during the developmental stages of these PROMs. Consumer involvement in
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PROM development is essential as it is only patients who can determine outcome relevance
and comprehensibility of the instrument.46,47 Previous studies have indicated that lack of
patient involvement affects the sensitivity, validity and response of the questionnaire tool,48,49
in which a 2017 study showed patient involvement had not increased in PROM development
over time.19

The study methodology itself is one of the main strengths of this study. Utilization of CI not
only aided in the refinement of the statements in the tool, but also enabled identification of
limitations which in turn assisted in the modification of the questionnaire construct that
defines HRQOL. This study also had certain limitations. The onset of COVID-19 during the
course of this study hindered the participant recruitment process, thereby impacting the study
progress. Administering CI to a small sample size contributed to the second limitation as
sampling variation could have increased with even more participant recruitment where
evaluating and reviewing the contents of the items could have improved. Even though
research has suggested that it is ideal to recruit between seven to 10 participants to check and
confirm participant’s item comprehension, the variability in the participant number depends
upon factors such as maximum sampling variation, questionnaire complexity and participant
understanding of the items.50
Conclusion
The current study utilized a systematic process to develop an OC specific PROM and
highlights the value of CI for questionnaire item modification and content validity. Validation
of the PROM in a larger sample and evaluation of its psychometric properties is an essential
next research project.
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Chapter summary
This chapter has reported the analysis and results of data obtained from Phase Two.

To our knowledge, this is the first study to use Cognitive Interviewing (CI) to refine
and validate items for an OC-specific tool. The application of a CI technique using the
concurrent think-aloud protocol enabled a better understanding of the thought process of
participants and use their feedback to develop the tool. The study also found aspects that the
study participants found important and relevant were not included in the current OC-specific
tools. This suggested the need to create a unique tool tailored specifically for OC patients
through their meaningful participation in the development of the tool.

The themes that emerged from the data revealed the problems related to item
interpretations and the overall structure of the tool. The qualitative technique not only
allowed the items to be refined and moreover helped the researcher develop a method by
identifying both HRQOL and contextual factors for HRQOL. It also enabled the researcher
to better construct the final draft instrument by including all information collected during
Phase One.

Upon study completion, it was recognised that CI could be considered as a method for
enhancing the design of the questions as it played a significant role that allowed data
validation to be achieved. Moreover, additional benefits were accompanied such as it gave an
opportunity for a good partnership between participants and the researcher, provided the
respondent a capacity to fulfill the part of an evaluator and narrator, helped to understand the
value of the significance of the items and helped to examine the credibility of the
questionnaire design.
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Chapter Six: Discussion & Conclusion
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Overview
This thesis outlines the development of a draft HRQOL PROM specifically for
women with OC, through patient involvement at each phase of the tool development. The
tool creation was conducted in two sequential phases, to address the gaps identified. Phase
One employed preliminary work using community conversation, followed by semi-structured
telephone interviews and focus groups. The qualitative dataset collected during Phase One
paved the way to the subsequent phase, Phase Two, by employing CI using the CTA
procedure. As a result, the two studies have been structured to answer the research questions
and address the limitations in the current OC tools. The results of the studies collectively
offered a detailed, theoretically driven interpretation of patient results with practical
implications for the further development of OVArian cancer health related Quality of Life
(OVAQOL) scale, a PROM tool that measures three core domains of HRQOL in women
diagnosed with OC: physical and functional status, emotional and social.

Key priorities of outcomes identified and described by women diagnosed with OC
This research utilised a ‘ground-up’ approach to holistically identify various outcomes
that were derived from the patients’ perspectives. Findings from the study conducted in Phase
One explored a wide range of challenges faced by women living with OC and their relative
concerns were heard, ranging from pre-diagnosis to post-treatment and beyond. The six
themes described both HRQOL outcomes and their contextual factors.

As described in Chapter Four, many of the women described experiencing various
symptoms including abdominal/bowel discomfort, fatigue, toilet urgency. Even though these
symptoms are not disease specific nor gynaecological (Bankhead et al., 2005), OC symptom
related studies indicate women experiencing gastrointestinal and urinary-related problems
where the frequency, severity and persistence of these symptoms will be higher in the months
prior to having a diagnosis (Bankhead et al., 2008; Ebell et al., 2016; Freij et al., 2018;
Natarajan et al., 2018).

Experiencing a delay in the clinical diagnosis of the disease was another key issue
identified from this study. The study data identified various factors that contribute to the
delay. Primarily, in the absence of an effective screening tool or specific symptoms, the
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majority of cases of OC are diagnosed at advanced stages (III & IV) (Miranda & Ahmed,
2016) often resulting in adverse disease outcomes (Buys et al., 2011). There is an urgent need
to develop new strategies for screening, and early detection as the analysed data illustrates
that women with delayed diagnosis faced various challenges including emotional,
informational and lack of adequate services. Further to the results displayed in chapter four, it
was also identified that potentially some GPs also contributed to the diagnostic delay. The
identified factors include excessive time span to make the right diagnosis, ignorance of
disease symptoms, becoming unaware of the symptoms assuming it referred to urinary or
perimenopausal problems. Reports of past studies support our findings that women follow
complex referral paths before being correctly diagnosed. Most women are initially presented
with observed and persistent symptoms in primary care. Several studies suggest that primary
care professionals have a significant role in identifying the symptoms and signs of the disease
and taking timely evidence-based decisions on further investigations and referrals (Bankhead
et al., 2008; Funston et al., 2018; Williams et al., 2019). In order to alleviate the incidence of
delayed diagnosis, recent research suggests that GPs should take detailed family histories to
identify women who may be at increased OC risk, and perform abdominal-pelvic
examinations, review recurring symptoms and send referrals without delay to gynaecological
cancer clinics (Funston et al., 2018).

HRQOL has become a well-recognised concept in cancer care, with qualitative
datasets clearly showing that physical, functional ability, emotional and social well-being in
women were significantly decreased, during post-diagnosis and treatment and that it's a
challenge to manage HRQOL during the clinical journey. It was recognised that patients’
HRQOL could be improved through better patient-clinician communication as it would help
patients raise their concerns without hesitation and aid in treatment symptom management
(Greenhalgh et al., 2018; Street, 2013). In addition, it was also found that the inclusion of
patients in informed decision-making will help maximise patient-centred care (Elshaug et al.,
2017; Lavallee et al., 2016).

Further, the qualitative data indicated many challenges in traversing the disease
journey especially when diagnosed with a chronic illness such as OC, consistent with the
findings of a recent study (Ahmed-Lecheheb & Joly, 2016). Our research data showed that
not only the long-term side effects of the treatments were impacted but contextual factors of
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HRQOL such as financial issues, interaction with HPs, information and service challenges
and patient coping strategies were also highly compromised. Based on the richness of the
data that was collected, various concepts of patient healthcare service satisfaction and
resilience were explored further that formed two important contextual factors of HRQOL.

Several challenges concerning patient satisfaction with the services provided
including those provided by GPs were identified. Challenges such as lack of communication
with and between HPs; receiving reliable information in relation to financial assistance,
treatments, support and service programmes; inadequate services offered by HPs including
GPs in relation to patient concerns being heard, the extent of support provided to patients and
their active involvement in patient clinical trajectory were identified. Patient satisfaction is a
vital factor that provides healthcare professionals with useful data on the quality of their
treatment and helps them to assess the effectiveness of their service (Ullah et al., 2020).
Studies have found that patient satisfaction with both healthcare services and the system can
be measured for better patient evaluation and improvement of their HRQOL (Davidson et al.,
2017; Senić & Marinković, 2013) as a recent study shows that poor patient satisfaction has an
association with psychological symptoms such as anxiety and depression (Kavalnienė et al.,
2018).

Despite the numerous challenges faced, patients shared their individual strategies to
exact a measure of control over the management of their disease including dietary
adjustments and lifestyle activities, family/friend support and having to connect with nature
and their spiritual beliefs. Moreover, resilience methods such as individual self-empowerment
were also identified. Having a determined mind, sense of humour, positive attitude,
adaptability of illness and looking forward to the future were used across their clinical
journey. Past studies suggest that self-management techniques should be used by patients
living with chronic illness where social support is a significant component for patients at
advanced cancer stage (Schulman‐Green et al., 2012; Wen et al., 2017).

Based on the study findings, patient-clinician communication should be progressed to
discuss and understand individual HRQOL outcomes of patients with OC. One of the
mediums to communicate these outcomes is through the self-administration of PROM tools.
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This study has found the solution by taking the initial step in developing a unique OC PROM
through patient involvement that measures all domains of HRQOL. Research has also
demonstrated that involving patients during each stage of PROM development can yield a
PROM instrument that is valid and comprehensible to patients. Further, implementation of
these measurement tools into both clinical care and research serves as a key component in
delivering value-based patient-centred care (Johansen & Saunders, 2017). Measuring patient
experiences such as disease and treatment related symptoms (frequency, severity and
duration) and HRQOL, can aid in assessing individual treatment progress and disease
recurrence.

Identification of items describing HRQOL & contextual factors for HRQOL
Since the Phase One outcomes captured a rich mix of challenges faced during the
clinical journey, it was vital to distinguish the outcomes that accurately measured HRQOL
and its contextual factors. The emergence of four broad themes with regards to item
comprehensions and questionnaire construct enabled outcomes to be refined and
operationalised into respective sections that define and measure HRQOL and its contextual
factors, thereby achieving content validity.

Overall, the development of a HRQOL PROM should place importance on factors
related to the women’s HRQOL. HRQOL is a multidimensional aspect and is defined by the
World Health Organisation as “a state of complete physical, mental and social well-being and
not merely the absence of disease or infirmity” (World Health Organisation, 2014). Within
the four broad themes identified, the student researcher was able to identify different aspects
that describe HRQOL of women diagnosed with OC and classify them according to these
three domains to develop the OVAQOL measure. In addition, recent studies indicate that
HRQOL surveillance is especially relevant in advanced cancer care because it increases the
clinical understanding of the patient's changing clinical needs (Basch et al., 2016; Etkind et
al., 2015).

No previous studies have been conducted to investigate various contextual factors of
HRQOL in patients with OC. The two studies conducted in this thesis also identified and
refined contextual factors. Factors such as disease and treatment-related symptoms,
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satisfaction with health services inclusive of informational and poor healthcare service
challenges, patient coping strategies and resilience methods were refined, evaluated and
segregated into appropriate sections with the overall questionnaire. It is equally important to
measure these variables as they influence patients’ HRQOL across the OC disease spectrum.
Some studies financial strains impact clinical outcomes and psychological wellbeing in
cancer patients (Perrone et al., 2016; Sharp et al., 2013), confirmed in a further study
conducted in 2018 (Chen et al., 2017). As patient satisfaction is a significant indicator of
HRQOL (Al-Abri & Al-Balushi, 2014) and findings from a Prostate cancer study identified
that patient satisfaction on healthcare service quality is an important element as patients
experienced better survival outcomes (Gupta et al., 2015). Resilience is defined as a baseline
trait that is identified and expressed in the face of adversity. According to a report, practicing
resilience across the cancer spectrum is critical as social assistance, hope, appreciation,
recognition helps to build inner strength and thereby alleviating distress and increases overall
patient well-being. (Molina et al., 2014). Based on information-rich qualitative data obtained,
the researcher was able to determine specific items that contributed to the creation of the
respective domains.

Identification of issues related to item interpretation and questionnaire construction
enabled the researcher to realise how interviewees' interpretations differed from the
researcher's intentions thereby validating the scale further. One of the identified shortcomings
of the existing validated OC PROMs is that have not developed a tool that integrates target
populations during its developmental stages. Thus, the research candidate believes that the
content of OVAQOL and contextual factors are likely to represent the consumer voice
because multiple processes for consulting with patients informed the development of the OCspecific tool, OVAQOL.

Findings from Phase One & Two led to the exploration of various limitations by using
the current validated OC tools. The limitations are widely discussed below and in Chapters
Two and Five respectively.
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Are the key outcomes identified through these processes different from existing
tools and if so, how are they different?
Through a multi-stage approach, this thesis enabled a comprehensive development of
an OC-specific tool that could measure various health domains and contextual factors of
women diagnosed with OC. Moreover, the student asserts that the newly developed tool is
distinctive from other existing OC tools.

Chapters Two and Five have addressed in-depth the numerous shortcomings
regarding the methodological procedures of the current OC tools. These include minimum to
no presence of patients during the stages of development. In addition, it was noted in the
respective chapters why an OC-specific measure is required to be developed which
adequately depicts the experiences of women diagnosed with OC. The findings obtained from
Phase One and Two (see Chapters Four and Five) enabled the researcher to distinguish
significant differences in the questionnaire structure and content and not just in the tool
development process.

What makes the developed measure unique?
Structure: OC Questionnaire and OVAQOL.
Taking into account the existing four OC tools, this is the first developed OC
questionnaire that contains HRQOL outcomes developed from the individual level. The
evaluated outcomes are structured in a way that can be used by any patient despite the clinical
stage they are in (Appendix 10). The purpose of aligning the set of outcomes in such a way
would help clinicians to better assess various challenges and provide value-based care on an
individual basis. Unlike FACT-O, EORTC QLQ C-30 and EORTC QLQ-OV28 were not
developed with domain-specific item banks that measure various aspects of HRQOL. In
addition, differences exist in their scale structure and an overall scoring system where QLQC30 score is generated by averaging responses to only two questions (global health and
quality of life), while FACT-G offers a summary of all 27 items (Luckett et al., 2011). FOSI
and MOST provide a symptom checklist focusing to measure disease/treatment symptoms
and side effects. Without considering the items measured in the questionnaire, it might be
hard for the clinicians to score and measure the patient outcomes which also seems to be
time-consuming.
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Item content: OC Questionnaire and OVAQOL.
Based on study findings in this thesis, the contents of both the OVAQOL measure and
its contextual variables are distinctive in nature. There is an agreement in the literature that
HRQOL should reflect more than just a symptoms rating, by integrating areas of physical,
functional, emotional and social aspects that go beyond clinical interventions and reflect on
the patients' health (Darling et al., 2020; Uy et al., 2020). A 2020 study that aimed to
construct an HRQOL instrument found that such instruments need to truly portray the
experiences and expectations of the target population whose health and wellbeing they
measure (Uy et al., 2020). With the limited invoke of OC patients throughout the creation of
the four OC instruments, it must be questioned that the conceptualisation, priorities and
health and wellbeing perspectives of women living with OC are accurately represented.
Second, while these instruments are considered adequately reliable for population-level
measurement of HRQOL, they may not calculate HRQOL with adequate accuracy to measure
patients' wellbeing over time as they traverse across the clinical journey. In addition, some
items in EORTC QLQ-C30 and FACT-G are cancer general and may not be specific to OC
patients.

It is believed that the outcomes defined in the OC questionnaire and OVAQOL
measure include all HRQOL domains. A study that was conducted a decade ago reported that
patient-clinician communication had been restricted to physical and functional HRQOL
without including psychological and social wellbeing aspects (Rodriguez et al., 2010).
Additional to a HRQOL scale, the OC questionnaire includes a disease/treatment symptom
checklist, patient satisfaction with healthcare services and resilience. HRQOL and wellbeing
are interconnected concepts. The positive facets of life such as positive feelings and
satisfaction with life measure patients’ wellbeing (People., 2020).

The differences addressed in this chapter make our measure distinctive because it
captures the true nature of numerous facets of living with OC as encountered by patients
during the course of their disease. Moreover, these outcomes have achieved content validity,
making a good evaluation of the questionnaire. Studies report that adequate content validity is
important when creating a measure. A 2009 study that assessed the measuring properties of
the 29 QOL tools verifies that content validity is critical and that the role of the target

94
population in the item development and selection is essential to achieve successful content
validity because patients are experts in their very own QOL (Albers et al., 2009).

Limitations
It is estimated that more than 4000 women are living with OC in Australia and that
this would equate to approximately 400 women living with OC in WA (Cancer Australia,
2019). Further, the incidence rate of OC is relatively low with only 1,510 new cases expected
to be diagnosed in Australia in 2019. Based on its population size, this translates to
approximately 150 new OC diagnoses per year in Western Australia. Thus, unlike other more
prevalent cancer types, such as breast cancer and colorectal cancer, the studies involved in
this thesis collected data using a relatively small sample size (Ong et al., 2017; Zerillo et al.,
2017). The small sample may not accurately represent the population of women with OC and
the results of the studies may not be generalizable. Furthermore, there could be an unveiling
bias where patient experiences may contribute to higher variability. As the emphasis of this
study was the importance of the participants' diverse perspectives, demographic variables
may not have been representative of the patient population.

As this study was conducted using semi-structured telephone interviews and focus
groups with OC patients, the accuracy of recollecting and recalling their experiences
especially at the time of diagnosis journey could be questioned. However, for most of the
participants, the challenges faced since receiving a diagnosis and subsequent management of
OC remain uppermost in their minds and thus the crux of their stories are unlikely to change.
Verbalizing thoughts is indeed one of the tasks required in CI. Challenges were encountered
in the administration of interview questions to less articulate respondents, as they were
continuously urged to engage in their full capacity to take part in CI. In addition, while
participants were briefed on the CTA procedure prior to the interview, the CI process itself
may have impacted how participants responded to the questions. Nonetheless, the extensive
literature review of OC and QOL will provide a triangulation in terms of the concepts and
priority areas defined by the women.

Strengths
There are also several strengths of this thesis. The highly centralised care of OC
patients in Western Australia facilitated participant recruitment, where the studies were
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conducted by the guidance of a supervisory team with the previous track record which
includes PROMs, qualitative, health and comprehensive outcomes researchers, and a
gynaecological oncologist. clinician. The utilisation of sound qualitative approaches ensured
a comprehensive exploration of the issues and provided rich and descriptive data that studies
of this type should seek (Mason, 2010). The usage of CI showed certain ways of enhancing
the tool through the refinement of items that will eventually allow future researchers to gather
better quality data on women's OC clinical experiences and thereby improve their HRQOL.
In addition, utilising a sequential approach, enabled a holistic understanding of patients’ and
carers’ lived experiences and the implications relating to the research problem. Finally, the
‘ground-up’ approach of involving patients from the commencement of initial phases will
ensure that priorities are clearly identified by the consumers (women with OC themselves).

Practical Implications
Through purposive sampling, the researcher candidate was able to capture the
perspective and experience of patients across the disease continuum. Although the purpose of
the study was to hear patient health outcomes and to establish a measure based on defined
data, the overall vision is to enhance the overall quality of cancer care. Based on the
collective data, several interventions could be designed and tested at the levels of patients,
health professionals and the healthcare system.

Chapter Four extensively explored numerous clinical implications of our findings.
One of the main issues raised was delayed diagnosis. With no specific screening tools or
early detection approaches to better identify OC, patient and clinician education on OC
symptom awareness should be promoted, thereby mitigating misdiagnosis. Moreover, it is of
vital importance to pay attention to subgroups including those who have had a relapse and
those who consider transitioning to palliative treatment with regular assessment and
evaluation (Lessard et al., 2019).

At the health professional and healthcare system level, it may be helpful to scale up
the early referral procedures for newly diagnosed individuals, with enhanced supervision to
support women to manage their HRQOL. The healthcare system and health professionals
should encourage patient advocacy techniques to improve illness self-management. Based on
the richness of qualitative data obtained, patients in various phases of their disease may
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obtain varying attention to clinical management. For example, recently diagnosed patients
encounter problems that are distinctive from those who are undergoing treatment, those who
had a recurrence, those who are considering shifting to palliative care and those who are
living with OC (Bergh et al., 2011; Vogel et al., 2013). Based on our findings, newly
diagnosed women should be sufficiently educated about the disease and its treatment. It
should also be confirmed that women have appropriate social support and that coping
methods, including having a positive attitude to the illness combined with techniques of
resilience such as a determined mind and making plans to look forwards, should be practiced
managing the diagnosis as the thought of dying is inevitably present in women.
Empowerment and psychological strategies would be suitable for those who have had a
relapse while coping strategies and daily task accomplishments can be provided to those
transitioning from oncology to palliative care in order to keep a balance of their HRQOL.
Those living with OC may also benefit from regular follow-up sessions. These initiatives and
recommendations could lead to the high provision of quality care by focusing on clinical
pathways for various patients’ groups and aid in better patient outcomes.

Implications for future research
The studies conducted in this thesis led to the development of an OC-specific tool
through the implementation of qualitative approaches. As a continuation of the work done
thus far, future studies should be undertaken to field test and evaluate its psychometric
properties such as specificity, validity, reliability, and evaluation of its feasibility in clinical
care and trials.

In this thesis, it was identified that there was minimal to no involvement of patients in
the developmental processes of existing OC tools. Therefore, a relevant starting point for
potential studies in OC could undertake research using a similar framework in the
development of other cancer specific PROMs for OC and general PROMs. We also
recommend studies that choose to use CI, either by spreading the administration of the
questionnaire over two days or by assigning separate parts of the questionnaire to different
participants.
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This thesis explored and identified outcomes across the OC disease spectrum. The
research candidate believes that treatment-related outcomes should be explored further.
Another path for future study will then be to develop OC treatment specific PROMs to
achieve a thorough understanding of OC treatments and their maintenance therapies.
Likewise, MOST, which measures signs and symptoms of patients undergoing Carboplatin
chemotherapy, PROMs relating to radiotherapy and immunotherapy outcomes should also be
developed.

Eventually, researchers should be transparent about the chosen methodology they
have taken with respect to the PROM development, taking account of such topics including
the expertise, time commitment, the scope of existing information and literature.

Conclusion
The potential of PROMs to improve the care of cancer survivors is increasingly
recognised because they allow accurate measurement of a range of outcomes through the
patient’s lens and throughout a patient’s clinical journey. Important aspects of HRQOL and
contextual factors for women with OC were identified in Phase One, such as the need for
mitigation strategies to reduce diagnostic delay and enhance their HRQOL. Through Phase
Two, the content validity of the items was confirmed thereby confirming the specific
outcomes that contribute to accurately measuring HRQOL of women diagnosed with OC.
These findings uncovered a number of far-reaching implications for the experiences of
diagnosis and how women navigate the health care system whilst undergoing treatment. By
involving patients with OC, this thesis newly developed an agreed specific set of outcomes
that are different to existing tools both in terms of methodological design and questionnaire
content using a sequential mixed methods approach to help determine what was important to
patients in order to directly improve their HRQOL.

Chapter summary
While OC PROM instruments do exist, they are few in number, are beset with
limitations due to lack of patient involvement during their development and may not
adequately cover associated symptoms during the whole disease trajectory. This chapter
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discussed and answered the research questions, and the primary and secondary research
addressed the gaps identified during the comprehensive literature review.
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PARTICIPANT INFORMATION SHEET
Patients First: Continuous Improvement in Cancer Care (CIC Cancer) project
Ovarian Cancer
You are invited to participate in the research project described below.
What is the project about?
Although patient information is collected throughout the clinical journey when someone is diagnosed with
ovarian cancer this information is divided both before, during and after cancer diagnosis. Much of the
information is not shared across cancer specialists and services and so is largely siloed, inaccessible for review
and incomplete. The Continuous Improvement in Care - Cancer (CIC Cancer) program of research wants to
enable health services to improve outcomes for patients through creating better information sharing
mechanisms about what is important to ovarian cancer patients and their carers. There is an urgent need for
linking information that helps identify gaps in care and assists in developing interventions to improve patient
outcomes while minimizing long term side-effects.
Who is undertaking the project?
This research is being conducted by Associate Professor Caroline Bulsara [Institute for Health Research, the
University of Notre Dame], Professor Jim Codde [Institute for Health Research, the University of Notre Dame],
Dr Paul Cohen [consultant gynecologist and obstetrician at the University of Western Australia], Ms Anne
McKenzie [WA Health Translation Network Lead consumer representative], Ms Briony Williams [WA Health
Translation Network consumer representative officer], Ms Judith Brown [consumer advocate with the
Ovarian Cancer Australia] .
What will I be asked to do?
The intended interviews are part of a wider study to engage you as a consumer who has been affected by
ovarian cancer, either as a patient or a carer. You are asked to participate in an interview by telephone about
your views on ways in which ovarian cancer has affected you and what you personally felt were the most
important outcomes to you as a patient / carer for someone with ovarian cancer.
The interview will take about 30 – 45 minutes and will be audio-recorded using a digital recording device. The
interview recording will then be transcribed and later on analysed by the researcher. If you have agreed to
being contacted again, the transcript will be sent to you for agreement regarding the content of the transcript
and to raise any issues or further comment regarding the transcript. This process should take no more than
two weeks from the time of the interview.
Are there any risks associated with participating in this project?
We don’t anticipate any risk to you in participating in this research project. However, if you find that questions
asked brings up difficult feelings, we have notified the Cancer Council of WA that they may be contacted
during the project timeframe. Their confidential support and information line is 13 11 20.
What are the benefits of the research project?
As stated, the main aim of the overarching CIC Cancer study is to define a set of relevant patient reported
outcomes measures (PROMs); in this instance for those who are affected by ovarian cancer. A crucial part of
the development of PROMs is to seek your input as a consumer who has experienced ovarian cancer.
Although you are not likely to benefit directly from this study, your self-identified key issues are central to
developing a PROMS set for ovarian cancer in the future.

What if I change my mind?

Participant Information Sheet template (October 2017)
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Participation in this study is completely voluntary. Even if you agree to participate, you are free to withdraw
from further participation at any time without giving a reason and with no negative consequences. You are
also free to ask for any information which identifies you to be withdrawn from the study.
Will anyone else know the results of the project?
Information gathered about you will be held in strict confidence. This confidence will only be broken if
required by law; data may be subject to subpoena, freedom of information request or legal reporting
obligations. The audio-recording from the interviews will be transcribed and stored on a password protected
computer and the audio-recordings will be deleted. Data collected through the focus groups will be deidentified and any responses that are deemed to be potentially identifiable will be removed at the point of
data analysis and will not be published as part of the results. Only the researchers conducting this study will
have access to individual information. Once the study is completed, the data collected from you will be deidentified and stored securely in the School of Nursing and Midwifery locked filing cabinet at The University
of Notre Dame Australia for at least a period of five years following the end of the 5-year research project
(i.e. to 2027). The results of the study will be published as a journal article and conference presentation.
Will I be able to find out the results of the project?
Once we have analysed the information from this study we will email out the key findings summary to those
participants who have elected to receive this information. You can expect to receive this feedback in one year
from the start of the study.
Who do I contact if I have questions about the project?
If you have any questions about this project please feel free to contact Caroline Bulsara at 9433 0217 or email
caroline.bulsara@nd.edu.au. We are happy to discuss with you any concerns you may have about this study.
What if I have a concern or complaint?
The study has been approved by the Human Research Ethics Committee at The University of Notre Dame
Australia (approval number reference 018158F). If you have a concern or complaint regarding the ethical
conduct of this research project and would like to speak to an independent person, please contact Notre
Dame’s Research Ethics Officer at (+61 8) 9433 0943 or research@nd.edu.au. Any complaint or concern will
be treated in confidence and fully investigated. You will be informed of the outcome.
How do I sign up to participate?
If you are happy to participate, please sign both consent forms which has been sent through with the
information sheet, keep one for yourself and mail the other to me in the envelope provided / contact the
researchers. Thank you for your time. This sheet is for you to keep.
Yours sincerely,
Signature removed for privacy

RESEARCHER NAME/S
A/Professor Caroline Bulsara
Ms Anne McKenzie
Ms Briony Williams
Ms Jude Brown
Dr Paul Cohen
Professor Jim Codde

Participant Information Sheet CIC Cancer Ovarian Focus group (November 2018)
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PARTICIPANT INFORMATION SHEET
Patients First: Continuous Improvement in Cancer Care (CIC Cancer) project
Ovarian Cancer Focus Groups
You are invited to participate in the research project described below.
What is the project about?
Although patient information is collected throughout the clinical journey when someone is diagnosed with
ovarian cancer this information is divided both before, during and after cancer diagnosis. Much of the
information is not shared across cancer specialists and services and so is largely siloed, inaccessible for review
and incomplete. The Continuous Improvement in Care - Cancer (CIC Cancer) program of research wants to
enable health services to improve outcomes for patients through creating better information sharing
mechanisms about what is important to ovarian cancer patients and their carers. There is an urgent need for
linking information that helps identify gaps in care and assists in developing interventions to improve patient
outcomes while minimizing long term side-effects.
Who is undertaking the project?
This research is being conducted by Associate Professor Caroline Bulsara [Institute for Health Research, the
University of Notre Dame], Professor Jim Codde [Institute for Health Research, the University of Notre Dame],
Dr Paul Cohen [consultant gynecologist and obstetrician at the University of Western Australia], Ms Anne
McKenzie [WA Health Translation Network Lead consumer representative], Ms Briony Williams [WA Health
Translation Network consumer representative officer], Ms Judith Brown [consumer advocate with the
Ovarian Cancer Australia] .
What will I be asked to do?
The intended focus groups are part of a wider study to engage you as a consumer who has been affected by
ovarian cancer, either as a patient or a carer. You are asked to participate in a focus group interview about
your views on ways in which ovarian cancer has affected you and what you personally felt were the most
important outcomes to you as a patient / carer for someone with ovarian cancer.
The focus group interview will take about 1 ½ hours (including refreshment time) and will be audio- recorded
using a digital recording device. The focus group recording will then be transcribed and analysed by the
researcher. If you have agreed to being contacted again, the transcript will be sent to you for agreement
regarding the content of the transcript and to raise any issues or further comment regarding the transcript.
This process should take no more than 1 month from the time of the focus group.
Are there any risks associated with participating in this project?
We don’t anticipate any risk to you in participating in this research project. However, if you find that
questions asked brings up difficult feelings, we have notified the Cancer Council of WA that they may be
contacted during the project timeframe. Their confidential support and information line is 13 11 20.
What are the benefits of the research project?
As stated, the main aim of the overarching CIC Cancer study is to define a set of relevant patient reported
outcomes measures (PROMs); in this instance for those who are affected by ovarian cancer. A crucial part of
the development of PROMs is to seek your input as a consumer who has experienced ovarian cancer.
Although you are not likely to benefit directly from this study, your self-identified key issues are central to
developing a PROMS set for ovarian cancer in the future.

Participant Information Sheet template (October 2017)
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What if I change my mind?
Participation in this study is completely voluntary. Even if you agree to participate, you are free to withdraw
from further participation at any time without giving a reason and with no negative consequences. You are
also free to ask for any information which identifies you to be withdrawn from the study.
Will anyone else know the results of the project?
Information gathered about you will be held in strict confidence. This confidence will only be broken if
required by law; data may be subject to subpoena, freedom of information request or legal reporting
obligations. The audio-recording from the focus groups will be transcribed and stored on a password
protected computer and the audio-recordings will be deleted. Data collected through the focus groups will
be de-identified and any responses that are deemed to be potentially identifiable will be removed at the
point of data analysis and will not be published as part of the results. Only the researchers conducting this
study will have access to individual information. Once the study is completed, the data collected from you
will be de-identified and stored securely in the School of Nursing and Midwifery locked filing cabinet at The
University of Notre Dame Australia for at least a period of five years following the end of the 5-year research
project (i.e. to 2027). The results of the study will be published as a journal article and conference
presentation.
Will I be able to find out the results of the project?
Once we have analysed the information from this study we will email out the key findings summary to those
participants who have elected to receive this information. You can expect to receive this feedback in one year
from the start of the study.
Who do I contact if I have questions about the project?
If you have any questions about this project please feel free to contact Caroline Bulsara at 9433 0217 or email
caroline.bulsara@nd.edu.au. We are happy to discuss with you any concerns you may have about this study.
What if I have a concern or complaint?
The study has been approved by the Human Research Ethics Committee at The University of Notre Dame
Australia (approval number reference 018158F). If you have a concern or complaint regarding the ethical
conduct of this research project and would like to speak to an independent person, please contact Notre
Dame’s Research Ethics Officer at (+61 8) 9433 0943 or research@nd.edu.au. Any complaint or concern will
be treated in confidence and fully investigated. You will be informed of the outcome.
How do I sign up to participate?
If you are happy to participate, please sign both consent forms which has been sent through with the
information sheet, keep one for yourself and mail the other to me in the envelope provided / contact the
researchers. Thank you for your time. This sheet is for you to keep.
Yours sincerely,
Signature removed for privacy

RESEARCHER NAME/S
A/Professor Caroline Bulsara
Ms Anne McKenzie
Ms Briony Williams
Ms Jude Brown
Dr Paul Cohen
Professor Jim Codde
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Appendix 4: Consent Form-Semi-structured telephone interviews
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CONSENT FORM
Patients First: Continuous Improvement in Cancer Care (CIC Cancer) project
(Ovarian Cancer)

• I agree to take part in this research project.
• I have read the Information Sheet provided and been given a full explanation of the purpose of this
research project and what is involved.
• I understand that I will participate in a one on one telephone interview and that the interview will be
audio-recorded.
• The researcher has answered all my questions and has explained possible risks that may arise as a result
of the interview and how these risks will be managed.
• I understand that I do not have to answer specific questions if do not want to and may withdraw from
participating in the project at any time without prejudice.
• I understand that all information provided by me is treated as confidential and will not be released by
the researcher to a third party unless required to do so by law.
• I agree that any research data gathered for the study may be published provided my name or other
identifying information is not disclosed.

Name of participant

Signature of participant

Date

• I confirm that I have provided the Information Sheet concerning this research project to the above
participant, explained what participating involves and have answered all questions asked of me.

Signature of Researcher

CIC Cancer Ovarian Focus Group
Nov 2018

Date
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Appendix 5: Consent Form-Focus groups
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CONSENT FORM
Patients First: Continuous Improvement in Cancer Care (CIC Cancer) project (Ovarian
Cancer)

• I agree to take part in this research project.
• I have read the Information Sheet provided and been given a full explanation of the purpose of this
research project and what is involved.
• I understand that I will participate in a focus group and that the focus group will be audio-recorded.
• The researcher has answered all my questions and has explained possible risks that may arise as a result
of the interview and how these risks will be managed.
• I understand that I do not have to answer specific questions if do not want to and may withdraw from
participating in the project at any time without prejudice.
• I understand that all information provided by me is treated as confidential and will not be released by
the researcher to a third party unless required to do so by law.
• I agree that any research data gathered for the study may be published provided my name or other
identifying information is not disclosed.

Name of participant

Signature of participant

Date

• I confirm that I have provided the Information Sheet concerning this research project to the above
participant, explained what participating involves and have answered all questions asked of me.

Signature of Researcher

CIC Cancer Ovarian Focus Group
Nov 2018

Date
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Appendix 6: Ethics Approval Letter (Phase Two)
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25 February 2020

A/Prof Caroline Bulsara & Sharolin Boban
Institute for Health Research
The University of Notre Dame Australia
Fremantle Campus

Dear Caroline and Sharolin,
Reference Number: 2020-010F
Project title: “Implementation of patient involvement in the development of a patient-reported
outcome measure for ovarian cancer- Cognitive Interviewing using Think Aloud procedure.”
Your response to the conditions imposed by the University of Notre Dame Human Research Ethics
Committee (HREC) has been reviewed in accordance with the National Statement on Ethical Conduct in
Human Research (2007, updated 2018). I am pleased to advise that ethics approval has been granted for
this proposed study.
Other researchers identified as working on this project are:
Name

School/Centre

Role

A/Prof Jenny Downs

Telethon Kids Institute

Co-Supervisor

Prof Jim Codde

Institute for Health Research

Co-Supervisor

Dr Paul Cohen

University of Western Australia

Co-Supervisor

All research projects are approved subject to standard conditions of approval.
Please read the attached document for details of these conditions.

On behalf of the Human Research Ethics Committee, I wish you well with your study.

Yours sincerely,

Signature removed for privacy
Dr Natalie Giles
Research Ethics Officer
Research Office
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Appendix 9: Draft set of interview statements for Phase Two
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INTRODUCTORY QUESTIONS
Demographics
Q1. What is your name? ____________________________
Q2. What is your current age (years)? ____________________________
Q3. What is your suburb/postcode? ____________________________
Q4. What is the highest level of education you have COMPLETED?
Some primary
school

Completed
primary

Some high
school

Completed high
school

TAFE
certificate

University
undergraduate
degree

University
postgraduate
degree

Other (specify) ____________________________

Q5. What is your MARITAL STATUS?
Single / never
married

Married / de
facto

Separated /
divorced

Widowed

Q6. Do you have children? Yes

No

Q6a. If yes, please specify their gender and age
Child

Gender

Age

Child 1
Child 2
Child 3
Child 4
Child 5
Other children

Q7. Which of the following best describes your employment status at time of your diagnosis?
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Full time paid work

Part time
paid work

Home duties

Studying

Currently
looking for
work

Retired

Disability pension

Other (specify) ____________________________

Q7a. Which of the following best describes your current employment status?

Full time paid work

Part time
paid work

Home duties

Studying

Currently
looking for
work

Retired

Disability pension

Other (specify) ____________________________

Q8. Do you have a health care card? (please circle one) Yes / No/ Not sure
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Cancer History
Q9. Were you previously diagnosed with other cancer types before Ovarian Cancer (e.g. breast,
colorectal)?
(please circle one) Yes / No
If Yes, could you please specify? (Type of cancer(s) & Time when you received a diagnosis
(months/years))
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________

Q10. Were you aware of any genetic or hereditary issues that you might have had prior to receiving
Ovarian Cancer Diagnosis (e.g. BRCA gene; Breast/Colorectal/Ovarian cancer in family members ,
etc)?
(please circle one) Yes / No
If Yes, please provide the details.
__________________________________________________________________________________
__________________________________________________________________________________
__________________________________

Q11. When did you receive your diagnosis of Ovarian Cancer (month/year)? ___________

Q12. At what stage was the cancer when you received the diagnosis?___________

Q13. Have you had a cancer recurrence? If yes, have you received any treatments?
_______________________
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Section 1: Clinical Diagnosis
Q1.
Yes

No

Don’t
Can’t
know remember

Yes

No

Don’t
Can’t
know remember

My ovarian cancer was diagnosed accidentally (e.g.
during surgery, emergency presentation at the
Emergency Department at the hospital)

Q2.

Had no obvious signs and symptoms

If the answer to Q2 is Yes, please go to Section 2, page.6.

Q3. The following questions are about the disease signs and symptoms and symptom
presentation challenges you may have experienced prior to receiving a diagnosis. Please
mark one answer per statement.
For each statement, please rate the overall impact of following symptoms on your wellbeing. Before I received my diagnosis, I…..
Severe Moderate Mild None
Had abdominal and bowel pain/discomfort (e.g.
bloating, constipation)
Had joint pain
Had menopausal symptoms
Had pain in my vaginal area
Had the sensation of needing to go to the toilet more
frequently
Experienced eye issues (eg. Itchy eyes)
Felt fatigued (e.g. tiredness, lack of energy)
Gained weight
Wasn’t really aware of my symptoms as part of ovarian
cancer (i.e. I thought they were due to something else,
e.g. menopausal symptoms)

152

Q4. Please describe other challenges that you might be experiencing or have
experienced in terms of your physical health:
Severe Moderate Mild None
ABCD-
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Section 2: Chemotherapy
Q1. Have you received chemotherapy in the past five years? (please circle one) Yes/No
If the answer is No, please go to Section 3, page.8.
Q2. How many full cycles of chemotherapy treatment have you received to date?
_______________________
Q3. When was the last cycle of chemotherapy you have completed (month/year)?
_______________________
Q4. The following questions specifically ask about the challenges (e.g. side effects,
chemotherapy administration) you have experienced during or after receiving
chemotherapy. Please mark one answer per statement.
For each statement, please rate the overall impact of following side effects on your wellbeing. During my chemotherapy, I experienced…..
Severe Moderate Mild None
Back pain (mild, moderate, severe)
Bloating with Cisplatin
Blood clots due to collapsed veins
Bowel problems (e.g. diarrhoea, constipation, bloating)
Carboplatin side effects
Cardiac arrest at time of chemo administration
Collapsed veins
Fatigue (tiredness, lack of sleep)
Frequent urgency to pass urine
Hair loss
Issues receiving chemo as an out-patient (e.g. chemo at
home)
Issues receiving PICC line treatment
Joint pain
Loss of appetite
Medication related side effects (e.g PEG allergy,
Phenergan)
Memory loss
Mouth ulcer/s
Mucositis
Nausea
Neuropathy
Pain
Poor balance
Taste disorder with Olaparib
Tinnitus
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Q5. Please describe other chemotherapy related challenges you have experienced:
Severe Moderate Mild None
ABCD-
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Section 3: Surgery
Q1. Have you undergone a treatment related surgery in the past five years? (please circle
one) Yes/No
If the answer is No, please go to Section 4, page.9.
Q2. How many surgeries have you received to date? _______________________
Q3. When was the last surgery you have undergone (month/year)?
_______________________
Q4. We would like to know any concerns and/or challenges that you may have faced after
undergoing surgery. Please mark one answer per statement.
For each statement, please rate the overall impact of the following challenges on your wellbeing. I experienced…..
Severe Moderate Mild None
Temporarily cessation of chemotherapy due to surgery
Anaesthetic issues during the surgery (e.g. fault of
Anesthesiologist)
Fluid filled stomach post-surgery
Weight loss
Sudden onset of menopause
Difficulties with Stoma Bag
Inability to have children

Q5. Please describe other surgery related challenges you have experienced:
Severe Moderate Mild None
ABCD-
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Section 4: Complementary therapies
Q1. Have you received any alternative treatments? (please circle one) Yes/No
If the answer is No, please go to Section 5, page.10.
Q2. Please provide the details of any alternative cancer treatments you have received in the
past five years:___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
__________________________________________
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Please complete all the following sections, from pages.10-16.
Section 5: Emotional Well-Being
Now, we would like to ask you about your well-being in terms of your feelings/emotions.
When we talk about emotional well-being we are talking about any feelings, worries or
concerns that you may have had across the course of the disease.
Please tick one answer per statement. Since my diagnosis of ovarian cancer….
SA
I am frustrated by not being active or able to exercise (as I used to)
I feel powerless at not making decisions myself (e.g. both small decisions
and larger decisions) about my care
I feel that I have lost my sense of who I am
I feel that there is a lack of awareness around this disease by others
I feel there is little awareness of ovarian cancer outside of my family and
close friends (e.g. lack of social awareness)
I feel valued because I can still contribute to the workforce (I am in paid
employment)
I find it difficult to stay strong in front of others
I find it hard to stay strong for myself
I have been embarrassed by the way my body looks (e.g. having a colostomy
bag, stoma bag)
I have been unwilling to accept my diagnosis
I have been worried about loss of income due to my illness
I have difficulty accepting the reality of my diagnosis
I have felt less feminine because of my illness
I have felt there was a lack of treatment choices offered to me
I have felt uncertainty when looking forward because of my illness
I have had concerns with medications that can have severe side effects
I have had difficulty in looking forward to the future
I have had emotional issues due to sudden menopause
I have had issues with not being able to have children (due to surgery)
I have lower self-esteem and feelings of self-worth due to my illness
There are some taboo topics (e.g. Euthanasia) that I have no one to talk to
about
CHALLENGING EMOTIONS
I have been in shock about my diagnosis and illness
I have felt angry about my illness
I have felt frustrated about my illness
I have felt stressed as a parent because of my illness
I have had negative feelings and emotions (e.g. stress, anger) when
participating in Ovarian Cancer support groups because of my illness
I felt frustrated during and/or after receiving a treatment (e.g. not able to
take part in activities that I used to do)
I have felt sick and unwell due to the side-effects of treatments I have
experienced
I have felt stressed during and/or after receiving a treatment

A

D

SD
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ANXIETY
I have been anxious because of my illness
DEPRESSION
I have been diagnosed with depression in relation to my illness
I have felt downhearted and sad because of my illness
FEAR
I have felt afraid (of illness, treatment and prognosis)
I have felt afraid of dying from my illness
I have felt afraid that the cancer will come back again
ISOLATION
I felt like I was being categorised (e.g. physical appearance-hair loss) because
of my illness
I have felt isolated socially because of my illness
RELATIONSHIPS
I found it difficult to understand my carer’s/partner’s feelings since my
diagnosis
My family/friends are generally not supportive of me at this time
My family/friends have reacted unexpectedly to my illness
My partner and I experience a lack of intimacy since my diagnosis
My partner needs time for him/herself since my diagnosis
People that I was close to have withdrawn from me since my diagnosis
HEALTH SERVICES
I feel that I have been given false hope by health professionals
I feel that the health professionals are not listening to me (patient-centered care)
I feel that the health professionals have little empathy
I felt that health professionals lack treatment experience (ovarian specific)
I felt there is a lack of health professionals available
I have experienced unprofessional behaviour by health professionals
I have felt let down by the health system
I have felt that the health professionals are not really taking my needs into
consideration (e.g. denial of patient centered care)
I lack confidence in health professionals
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Section 6: Financial Wellbeing
Q1. The following statements are about other practical challenges you may have faced
during/after a particular treatment. We would like to know any financial challenges you may
have faced that have impacted your well-being.
Please tick one answer per statement. I experienced….
SA

A

D

Financial barriers due to living in a rural or remote place (e.g.
travelling difficulties to receive a treatment)
Barriers to undergoing surgery due to work commitments
Difficulties with ambulance cover costs (insurance)
Difficulties with car parking whilst attending appointments at the
hospital
Financial instability since my diagnosis
Lack of information regarding financial support (e.g. HBF, PBS)
Limited travel options for work or holiday (e.g. interstate, within the
state) due to my treatment
Out of pocket expenses due to my medical costs (e.g. surgery,
insurance cover issues, PET scan test, MRI tests)
A need for financial support (e.g. superannuation and/or disability
pension support, private health insurance)

Q2. Please describe other practical challenges (not mentioned above) that you have
experienced:
SA
ABCD-

A

D

SD

SD
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Section 7: Health Services
The following statements focus on issues you may have faced in relation to the services
provided to you once you were diagnosed with ovarian cancer. This includes any health
services provided including those provided by your GP.
Please tick one answer per statement and rate the overall impact of the following
challenges on your well-being.
SA A D SD
I feel there are less services provided to ovarian cancer patients compared
to other higher profile cancer types (e.g. Breast, Prostate)
I have experienced poor medical decision making by the health
professionals
I have had genetic testing (BRACA gene)
The health professionals I consulted about my symptoms did not consider
ovarian cancer
There are inadequate support service programs (e.g. counselling)
There is a lack of financial assistance with practical support (e.g. house
cleaning)
There is lack of communication between health professionals (e.g. GP and
specialists)
There is lack of opportunity to participate in clinical trials for new
treatments
There is lack of respite care for Ovarian Cancer patients (e.g. single
parents)
GP
I feel that my GP was biased and did not take my concerns seriously
because I am a woman
I felt that my GP contributed to the delay in my diagnosis
I had to be proactive and request that my GP refer me for testing
I presented at the hospital with specific symptoms (e.g. Abdominal
discomfort, Fatigue, bloating) that had not been identified by my GP
My GP is actively involved throughout my diagnosis and illness
Overall, I feel that my GP is supportive of me and my illness

161

Section 8: Communication & Informational Challenges
Now, we would like to know of any communication challenges you may have experienced in
particular with health professionals (e.g. lack of patient centered care, poor medical
decision making), including whether you have had trouble getting information during
active treatment.
Please tick one answer per statement and rate the impact of following challenges on your
well-being. I have experienced communication challenges in….
SA
An ability to meet my language needs (e.g. English not the first
language)
Receiving accurate information about my treatment and my illness
in general (e.g. hospital staff, specialists, nurses)
Accessing central and accessible ovarian cancer specific information
Shared communication & information between health professionals
Shared communication & information between hospital
departments
Shared communication & information with health professionals
Shared communication & information with the ambulance crew
Health professionals’ ovarian cancer knowledge
Health system information (e.g. lack of information provided after
receiving a treatment, lack of follow-up after receiving treatment)
Inability to ask questions of those providing treatment and services
Getting information regarding the OC Resilience Kit
Treatment information (i.e. options and side effects of each)
Lack of willingness to listen to my concerns

A

D

SD
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Section 9: Seeking Help & Coping Strategies
Now, we would like to know what helped you to cope and improve your sense of wellness
once you (i) were diagnosed and/or (ii) received active treatment. This includes whether or
not you sought help and what your main strengths were throughout your clinical pathway.
Please select one answer per statement and rate the impact of following challenges on your
well-being. I was able to cope better because …..
SA
I have prior medical knowledge and training (e.g. a health
professional such as a doctor or nurse)
I adjusted my diet and lifestyle activities (e.g. physical activities,
yoga, reflexology)
I aimed to stay positive throughout
I benefitted from available information (medical knowledge,
information provided by HPs)
I drew strength from my spiritual beliefs (e.g. religion, connecting
with nature)
I managed well with the support of my family and friends
I relied on being treated ‘normally’ by others
I sought informational help (e.g. Google, research, survivor stories)
I took symptom relief medications (e.g. Anti-Depressants) as
complementary to my treatment
The information I received from organisations helped me manage
my illness (e.g. Psychologist referrals, Cancer Council, Support
groups)

A

D

SD
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We would like to know how resilient you believe that are/were during your treatment.
Please mark one answer per statement and rate the impact of each statement on your wellbeing. In regards to managing my illness…..
SA
I have had a determined mind
I benefitted from having medical knowledge (professional &
training)
I drew strength from family and friends
I found time for myself
I gained adaptability to my illness
I had a positive attitude to the illness
I had a sense of humour
I kept calm
I looked forward to the future
I maintained a positive attitude in relation to my illness
I maintained a sense of gratitude
I maintained a sense of humour
I made plans to look forward
I refused to give up on myself
I took relief medication as an alternative (e.g. anti-depressants)

A

D

SD
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Appendix 10: Ovarian cancer questionnaire & OVArian cancer health related

Quality of Life (OVAQOL) scale
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Questionnaire for women with ovarian cancer

1.0 Information about you
Q1. What is your name? ____________________________
Q2. What is your current age (years)? ____________________________
Q3. What is the highest level of education you have COMPLETED?
Some primary
Completed
Some high
school
primary
school
Completed high
school

TAFE
certificate

University
undergraduate
degree

University
postgraduate
degree

Other (specify) ____________________________

Q4. What is your MARITAL STATUS?
Single / never
Married / de
married
facto

Separated /
divorced

Widowed

Q5. Do you have children? Yes
Q5a. If yes, please specify their gender and age
Child
Gender
Child 1
Child 2
Child 3
Child 4
Child 5
Child 6

No

Age
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Q6. Which of the following best describes your employment status when you received the
diagnosis?
Full time paid
work

Part time
paid work

Self-employed

Home Duties

Studying

Currently
looking for
work

Retired

Disability
pension

Other
(specify)

____________________________

Q7. Which of the following best describes your current employment status?
Full time paid
work

Part time
paid work

Self-employed

Home Duties

Studying

Currently
looking for
work

Retired

Disability
pension

Other
(specify)

____________________________

Q7a. If retired, did you retire early because of your diagnosis? (please circle one) Yes/No

Q8. Do you currently have a health care card? (please circle one) Yes / No/ Not sure
Q9. When did you receive your diagnosis of Ovarian Cancer (month/year)? ___________
Q10. Have you had a cancer recurrence (has your cancer returned or have you had a relapse of your
cancer)? (please circle one) Yes/No
Q10a. If yes, what treatments have your received? _______________________
Q10b. If yes, what are your current treatments? _________________________
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2.0 Symptom Checklist
The following questions are about the symptoms you may have experienced.
Please mark one answer per statement (i.e. Severe / Moderate / Mild / None / Not
applicable).
For each statement, please rate the overall impact of following symptoms.
During the past 4 weeks, I experienced…
Abdominal pain/discomfort
Back pain
Bloating
Blood clots due to collapsed veins
Collapsed veins
Constipation
Diarrhoea
Difficulties with the Stoma Bag
Fatigue (e.g. tiredness, lack of energy)
Frequent urgency to pass urine
Hair loss
Joint pain
Loss of appetite
Memory loss
Menopausal hot flushes/sweats
Mouth ulcers
Mucositis (Inflammation and ulceration of the
digestive tract, e.g., the gums or throat or
bowel)
Nausea
Neuropathy
Pain
Poor balance
Regret about my inability to have children
Taste disorder
Tinnitus (Ringing or noises in your ear or head)
Weight gain
Weight loss

Severe

Moderate

Mild

None

NA
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The following questions are about the treatments you may have received.
Q1. Have you ever received chemotherapy? (please circle one) Yes/No
If No, please go to Q5.
Q2. How many prior courses of chemotherapy have you had? _______________________
Q3. When was the last course of chemotherapy that you completed (month/year)?
_______________________
Q4. Are you currently on maintenance chemotherapy? (e.g. Olaparib or Avastin)
_______________________
Q5. Have you ever had surgery for Ovarian Cancer? (please circle one). Yes/No
If yes, how many surgeries have you received? _______________________
If No, please go to Section 3, page 5.
Q6. When did you last have surgery for your Ovarian Cancer (month/year)?
_______________________
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Health Related Quality of Life
Section 3: OVArian cancer health related Quality of Life (OVAQOL) scale
These questions ask about your physical, emotional and social wellbeing in relation to your
ovarian cancer. This is called health-related quality of life.

Physical domain
Please tick one answer per statement.
During the past 4 weeks…
I am bothered by my symptoms (e.g. pain,
altered appetite)
I am frustrated by not being able to exercise
(as I used to)
I am generally lacking energy to do what I
wanted to do
I am having difficulties sleeping well
I have felt frustrated that I could not take
part in usual activities because of my
treatments.
I have felt sick and unwell as side-effects of
my treatments
I have found it difficult to care for my family
and/or friends because of my illness

Always

Often

Sometimes

Rarely

Never
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Emotional domain
Please tick one answer per statement.
During the past 4 weeks…
I feel stressed for people around me that I
care for
I have been depressed in relation to my illness
I have been embarrassed by the way my body
has changed
I have been feeling anxious
I have been unwilling to accept my diagnosis
I have been worried about loss of income due
to my illness
I have felt afraid (of my illness, treatment
and/or prognosis)
I have felt afraid of dying from my illness
I have felt afraid that the cancer will come
back again
I have felt angry about my illness
I have felt downhearted and sad because of
my illness
I have felt frustrated about my illness
I have felt frustrated as there is uncertainty of
what is going to happen in the future
I have felt less feminine because of my illness
I have felt less self-worth due to my illness
I have felt powerless by not making decisions
myself (e.g. both small decisions and larger
decisions) about my care
I have felt stressed about my treatments
I have felt that I have lost my sense of who I
am
I have felt valued because of the work that I
can do (home, workforce)
I have found it difficult to stay strong in front
of others
I have found it hard to stay strong for myself

Always

Often

Sometimes

Rarely

Never
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Social domain
Please tick one answer per statement.
During the past 4 weeks…
I found it difficult to understand my
carer’s/partner’s feelings since my diagnosis
I have felt that my carer/partner actually
think/feel differently from how they are
acting in front of me
I have found it difficult to connect socially
with people because of my illness (e.g. at
work, in public)
My carer/partner has been able to support
my practical needs (e.g. driving to
appointments)
My family has been generally supportive of
me at this time
My friends have been generally supportive
of me at this time
My family/friends have reacted
unexpectedly (in a negative way) to my
illness
My partner and I have experienced a lack of
intimacy since my diagnosis
My partner has needed more self-time since
my diagnosis
People that I was close to have withdrawn
from me since my diagnosis

Always

Often

Sometimes

Rarely

Never
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Section 4: Satisfaction with health care services
The following statements focus on your satisfaction in relation to the services provided to
you in relation to ovarian cancer.
This includes any health services provided including those provided by your GP.
Please tick one answer per statement and rate the overall impact of the following
challenges on your well-being.
During the past 4 weeks…
Health professionals have not been willing to
listen to my concerns
Health professionals have not shared
communication & information between each
other (e.g. between hospital departments or
with GPs)
I have experienced difficulties in accessing
information and support regarding my
financial needs (e.g. information in relation
to the pharmaceutical benefit scheme or
income support)
I have felt that health professionals were not
really taking my needs into consideration
I have found it difficult to ask questions and
receive answers from those who are
providing treatment and services to me
I have not received accurate information
about my treatment (i.e. options and side
effects of each) and my illness (e.g. from
hospital staff, specialists, nurses)
There has been a lack of information about
the supports and service programs that I
could access (e.g. counselling)
There has been a lack of information and
opportunity to participate in clinical trials for
new treatments
There has been a lack of practical support
offered to me (e.g. house cleaning, home
maintenance)
GP
I feel that my GP has been supportive of me
and my illness
My GP has been actively involved throughout
my diagnosis and illness

Always

Often

Sometimes

Rarely

Never
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Section 5: Self-Sufficiency & Resilience
Now, we would like to know how resilient you believe that you are feeling in relation to
your illness.
Please mark one answer for each statement.
With regard to managing my illness and
during the past 4 weeks……
I have adjusted my diet and lifestyle activities
(e.g. physical activities, yoga, reflexology)
I have benefitted from having medical
knowledge (professional & training)
I have drawn strength by connecting with the
nature
I have drawn strengths from family
I have drawn strengths from friends
I have drawn strengths from my spiritual
beliefs (e.g. religion)
I have found time for myself
I have gained adaptability to my illness
I have had a positive attitude to managing my
clinical journey
I have had a sense of humour
I have had a strong sense of determination
I have kept calm
I have looked forward to the future
I have made plans to look forward
I have maintained a positive attitude in
relation to my illness
I have maintained a sense of gratitude for
what I am able to do/achieve
I have maintained a sense of gratitude to
family/friends
I have maintained a sense of humour
I have managed well with the support of my
family
I have managed well with the support of my
friends
I have refused to give up on myself
I have relied on being treated ‘normally’ by
others

Always

Often

Sometimes

Rarely

Never
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